haloperidol and Psychomotor Agitation studies

Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.

Psychomotor Agitation: A feeling of restlessness associated with increased motor activity. This may occur as a manifestation of nervous system drug toxicity or other conditions.

Research Excerpts

Excerpt	Relevance	Reference
"This is an open-label, parallel-group, randomized controlled trial to compare the efficacy and safety of dexmedetomidine and haloperidol for nocturnal hyperactive delirium in non-intubated patients at two HDUs of a tertiary hospital."	9.69	Dexmedetomidine versus haloperidol for sedation of non-intubated patients with hyperactive delirium during the night in a high dependency unit: study protocol for an open-label, parallel-group, randomized controlled trial (DEX-HD trial). ( Harada, H; Ikeda, K; Kamei, J; Kato, T; Kitajima, N; Kuriyama, A; Maeda, J; Matsuyama, A; Minami, T; Mizota, T; Ohtsuru, S; Sakai, Y; Sato, Y; Takatani, Y; Ueno, K; Watanabe, H; Yamaji, K; Yamashita, Y, 2023)
"To compare the efficacy and safety of scheduled low-dose haloperidol versus placebo for the prevention of delirium (Intensive Care Delirium Screening Checklist ≥ 4) administered to critically ill adults with subsyndromal delirium (Intensive Care Delirium Screening Checklist = 1-3)."	9.22	Preventing ICU Subsyndromal Delirium Conversion to Delirium With Low-Dose IV Haloperidol: A Double-Blind, Placebo-Controlled Pilot Study. ( Al-Qadheeb, NS; Devlin, JW; Pacheco, MN; Roberts, RJ; Ruthazer, RR; Schumaker, G; Skrobik, Y, 2016)
"To evaluate the clinical effectiveness, safety, and cost of dexmedetomidine for the treatment of agitated delirium refractory to haloperidol in nonintubated critically ill patients."	9.22	Dexmedetomidine for the Treatment of Hyperactive Delirium Refractory to Haloperidol in Nonintubated ICU Patients: A Nonrandomized Controlled Trial. ( Baeza, N; Cabré, L; Calizaya, M; Carrasco, G; Gimeno, G; Manzanedo, D; Portillo, E, 2016)
" Acutely agitated patients with schizophrenia or schizoaffective disorder (n = 67) were randomized to receive 10 mg IM olanzapine (n = 37) or 5 mg IM haloperidol plus 2 mg IM lorazepam (n = 30)."	9.20	Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: An open-label, randomized controlled trial. ( Chen, HH; Chen, YH; Hsieh, MH; Huang, CL; Huang, GH; Hwang, TJ; Hwu, HG, 2015)
"Oral haloperidol, risperidone, and olanzapine seem to be suitable for treating acute severe psychotic agitation in schizophrenia spectrum disorders."	9.19	Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine. ( Abderhalden, C; Horn, H; Maier, N; Moggi, F; Moskvitin, K; Müller, TJ; Strik, W; Walther, S, 2014)
"This study was a comparative investigation of the clinical efficacy and safety of intramuscular (IM) olanzapine, IM haloperidol, and IM levomepromazine in acute agitated patients with schizophrenia."	9.19	A naturalistic comparison study of the efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular levomepromazine in acute agitated patients with schizophrenia. ( Gen, K; Suzuki, H; Takahashi, Y, 2014)
" Previous studies have demonstrated that IM ziprasidone is efficacious and safe for treatment of agitation in schizophrenia."	9.17	Intramuscular ziprasidone versus haloperidol for managing agitation in Chinese patients with schizophrenia. ( Deng, H; Gao, C; Karayal, ON; Li, K; Pan, S; Shi, J; Shu, L; Tang, H; Vanderburg, D; Wang, G; Wang, X; Xie, S; Xu, X; Zhang, H; Zhao, J, 2013)
"Patients were randomized into 2 groups; in group 1, patients received 5mg of haloperidol intramuscularly and in group 2, patients received 5mg of morphine sulfate intramuscularly to control delirium symptoms."	9.17	Morphine is a reasonable alternative to haloperidol in the treatment of postoperative hyperactive-type delirium after cardiac surgery. ( Akgün, S; Atalan, N; Başaran, C; Efe Sevim, M; Fazlıoğulları, O, 2013)
"This randomized, parallel-group, open study investigated the efficacy and safety of risperidone oral solution (RIS-OS) in combination with clonazepam and intramuscular haloperidol for the treatment of acute agitation in patients with schizophrenia, and the study explored the possibility of decreasing the efficacy of an acute 6-week treatment by switching intramuscular haloperidol injection to RIS-OS."	9.16	Comparison of risperidone oral solution and intramuscular haloperidol with the latter shifting to oral therapy for the treatment of acute agitation in patients with schizophrenia. ( Chen, H; Fang, M; Huang, J; Li, LH; Li, Y; Liu, L; Wang, B; Wang, G; Wu, R; Ye, M; Zhang, L; Zhang, Q; Zhao, JP; Zheng, H; Zhou, J; Zhu, S, 2012)
"In patients with early-episode schizophrenia, aripiprazole demonstrates greater improvement than haloperidol on PANSS items related to social functioning."	9.14	Effect of aripiprazole versus haloperidol on PANSS Prosocial items in early-episode patients with schizophrenia. ( Baker, RA; Docherty, JP; Eudicone, J; Mankoski, R; Marcus, RN; Mathew, S; McQuade, RD, 2010)
"When comparing treatment effects on individual symptoms frequently occurring in patients with dementia, risperidone significantly improved symptoms of agitation, wandering, diurnal rhythm disturbance and anxieties, among other symptoms, compared with haloperidol."	9.12	Comparative efficacy of risperidone versus haloperidol on behavioural and psychological symptoms of dementia. ( Choi, SK; Greenspan, AJ; Suh, GH, 2006)
"This double-blind, placebo-controlled study investigated the efficacy and safety of intramuscular (IM) aripiprazole and IM haloperidol for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder."	9.12	Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. ( Andrezina, R; Carson, WH; Iwamoto, T; Josiassen, RC; Manos, G; Marcus, RN; Oren, DA; Stock, E, 2006)
"Intramuscular aripiprazole is effective in patients with acute agitation associated with schizophrenia, comparable to IM haloperidol, and enables convenient transfer to oral aripiprazole therapy."	9.12	Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study. ( Andrezina, R; Carson, WH; Manos, G; Marcus, RN; McQuade, RD; Oren, DA; Stock, E, 2006)
"We conducted a prospective double-blind study of accelerated dose titration of olanzapine in the treatment of newly admitted acutely agitated patients with schizophrenia."	9.11	Efficacy of accelerated dose titration of olanzapine with adjunctive lorazepam to treat acute agitation in schizophrenia. ( Ahl, J; Kinon, BJ; McMullen, E; Rotelli, MD, 2004)
"An intramuscular (IM) formulation of olanzapine has been developed because there are no rapid-acting IM atypical antipsychotic drugs currently available in the United States for treating acute agitation in patients with schizophrenia."	9.10	A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. ( Birkett, M; Breier, A; Brook, S; David, S; Dossenbach, M; Ferchland, I; Kiesler, G; Meehan, K; Palmer, R; Sutton, V; Taylor, CC; Wright, P, 2002)
"The authors evaluated the comparative efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular placebo for the treatment of acute agitation in schizophrenia."	9.09	Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. ( Alaka, KJ; Bernardo, M; Birkett, M; Bradley, P; Breier, A; David, SR; Ferchland, I; Krueger, J; Meehan, K; Reinstein, M; San, L; Saunders, JC; Wright, P, 2001)
"The authors compared the efficacy and side effects of trazodone and haloperidol for treating agitated behaviors associated with dementia."	9.08	A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. ( Berisford, MA; Gray, KF; Gunay, I; Mahler, ME; Sultzer, DL, 1997)
"To evaluate the effects of intramuscular aripiprazole in the treatment of psychosis-induced aggression or agitation (rapid tranquillisation)."	8.98	Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation). ( Jajawi, S; Jayaram, MB; Ostinelli, EG; Sayal, K; Spyridi, S, 2018)
"Haloperidol used alone is recommended to help calm situations of aggression or agitation for people with psychosis."	8.95	Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation). ( Adams, CE; Brooke-Powney, MJ; Li, X; Ostinelli, EG, 2017)
"To examine whether haloperidol plus promethazine is an effective treatment for psychosis-induced aggression."	8.93	Haloperidol plus promethazine for psychosis-induced aggression. ( Alexander, J; Allen, MH; Gandhi, P; Huf, G, 2016)
"Haloperidol, used alone is recommended to help calm situations of aggression with people with psychosis."	8.88	Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation). ( Adams, CE; Jones, H; Powney, MJ, 2012)
"The objective of this article is to assess the clinical characteristics of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder receiving aripiprazole, haloperidol, olanzapine, or placebo."	8.86	Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials. ( Assunção-Talbott, S; Barnes, TR; Buckley, P; Correll, CU; Eudicone, J; Kane, JM; McQuade, R; Pikalov, A; Sachs, G; Tran, QV, 2010)
"To examine the effects of oral or intramuscular chlorpromazine for psychosis induced agitation or aggression."	8.86	Chlorpromazine for psychosis induced aggression or agitation. ( Adams, CE; Ahmed, U; Jones, H, 2010)
"Haloperidol, which is commonly used to treat agitation in critically ill patients, has been associated with the development of neuroleptic malignant syndrome (NMS)."	8.85	Neuroleptic malignant syndrome in traumatic brain injury patients treated with haloperidol. ( Bellamy, CJ; Falcione, BA; Kane-Gill, SL; Seybert, AL, 2009)
"To examine whether haloperidol plus promethazine is an effective treatment for psychosis induced agitation/aggression."	8.85	Haloperidol plus promethazine for psychosis-induced aggression. ( Alexander, J; Allen, MH; Huf, G; Raveendran, NS, 2009)
"To examine whether haloperidol plus promethazine is an effective treatment for psychosis induced agitation/aggression."	8.82	Haloperidol plus promethazine for psychosis induced aggression. ( Alexander, J; Allen, MH; Huf, G, 2005)
"The CDCIG Specialized Register was searched to identify all available reports on haloperidol treatment of agitated dementia."	8.81	Haloperidol for agitation in dementia. ( Colford, J; Lonergan, E; Luxenberg, J, 2001)
" Evidence suggests that haloperidol was useful in the control of aggression, but was associated with increased side effects; there was no evidence to support the routine use of this drug for other manifestations of agitated dementia."	8.81	Haloperidol for agitation in dementia. ( Colford, J; Lonergan, E; Luxenberg, J, 2002)
"Practice guidelines recommend the use of low dose haloperidol when medication is needed to treat delirium with acute agitation in hospitalized older people."	7.79	Haloperidol overdosing in the treatment of agitated hospitalized older people with delirium: a retrospective chart review from a community teaching hospital. ( Dorokhine, I; Knapp, CM; Musuku, M; Patel, N; Zirker, W, 2013)
"The authors report a case of a patient, who in a few days after an abrupt discontinuation of clozapine and haloperidol developed agitated and confused state resembling neuroleptic malignant syndrome (NMS) and clozapine withdrawal symptoms at the same time."	7.73	Neuroleptic malignant syndrome and clozapine withdrawal at the same time? ( Aukst-Margetić, B; Margetić, B, 2005)
"This post hoc analysis used data from a multinational, double-blind, randomized, placebo-controlled study comparing the efficacy of olanzapine, haloperidol, and placebo in acutely agitated inpatients aged > or =18 years with schizophrenia conducted at hospitals in 13 countries."	7.73	A post hoc analysis of transitioning to oral treatment with olanzapine or haloperidol after 24-hour intramuscular treatment in acutely agitated adult patients with schizophrenia. ( Ahl, J; Battaglia, J; Houston, JP; Kaiser, CJ; Meyers, AL, 2005)
"This reanalysis of a previously reported pivotal clinical trial assessed whether quetiapine or haloperidol has benefits for the treatment of hostility and agitation among patients experiencing an acute exacerbation of schizophrenia."	7.72	A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia. ( Chengappa, KN; Goldstein, JM; Greenwood, M; John, V; Levine, J, 2003)
"We report on three patients with acute coronary syndromes who developed QT interval prolongation associated with intravenous haloperidol use."	7.70	Corrected QT interval prolongation associated with intravenous haloperidol in acute coronary syndromes. ( Block, PC; Douglas, PH, 2000)
"The phenomenon of restlessness, agitation, or cognitive disturbances experienced by dying patients is well-known in palliative care; more than half of these patients will experience delirium symptoms at end-of-life."	7.11	An open-label clinical trial of oral transmucosal haloperidol and oral transmucosal olanzapine in the treatment of terminal delirium at home. ( Chong, PH; Kan, AD; Koh, YH; Lin, K; Lyu, XJ; Yeo, ZZ, 2022)
" Both groups reported insomnia as the most common treatment-emergent adverse event, and no serious adverse event was reported."	6.79	A double-blind, randomized comparison study of efficacy and safety of intramuscular olanzapine and intramuscular haloperidol in patients with schizophrenia and acute agitated behavior. ( Chan, HY; Chen, CK; Chen, JJ; Chen, YS; Chou, SY; Ree, SC; Su, LW, 2014)
"In olanzapine-treated patients, improvement in BPRS agitation and positive symptom scores was significantly greater at weeks 4, 5, and 6 (agitation scores, p < or = ."	6.70	Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia. ( Hill, AL; Kinon, BJ; Milton, DR; Roychowdhury, SM, 2001)
"When droperidol was compared with placebo, for the outcome of tranquillisation or asleep by 30 minutes we found evidence of a clear difference (1 RCT, N = 227, RR 1."	6.53	Droperidol for psychosis-induced aggression or agitation. ( Khokhar, MA; Rathbone, J, 2016)
"This is an open-label, parallel-group, randomized controlled trial to compare the efficacy and safety of dexmedetomidine and haloperidol for nocturnal hyperactive delirium in non-intubated patients at two HDUs of a tertiary hospital."	5.69	Dexmedetomidine versus haloperidol for sedation of non-intubated patients with hyperactive delirium during the night in a high dependency unit: study protocol for an open-label, parallel-group, randomized controlled trial (DEX-HD trial). ( Harada, H; Ikeda, K; Kamei, J; Kato, T; Kitajima, N; Kuriyama, A; Maeda, J; Matsuyama, A; Minami, T; Mizota, T; Ohtsuru, S; Sakai, Y; Sato, Y; Takatani, Y; Ueno, K; Watanabe, H; Yamaji, K; Yamashita, Y, 2023)
"This was a pre-planned secondary analysis of a double-blind, randomized clinical trial comparing the use of a single dose of lorazepam plus haloperidol versus placebo plus haloperidol in patients with agitated delirium."	5.41	Association among rescue neuroleptic use, agitation, and perceived comfort: secondary analysis of a randomized clinical trial on agitated delirium. ( Bruera, E; Chen, M; Hui, D; Tang, M, 2021)
"We conducted a randomized clinical trial comparing the rapidity of onset, level of sedation, and adverse effect profile of ketamine compared to a combination of midazolam and haloperidol for behavioral control of emergency department patients with severe psychomotor agitation."	5.41	Rapid Agitation Control With Ketamine in the Emergency Department: A Blinded, Randomized Controlled Trial. ( Andolfatto, G; Barbic, D; Barbic, SP; Grunau, B; Honer, WG; Macewan, B; Qian, H; Scheuermeyer, FX; Wong, H, 2021)
"Haloperidol 0."	5.28	Brachial plexus palsy with the use of haloperidol and a geriatric chair. ( King, T; Mallet, L, 1991)
"The current study was a secondary analysis of a randomized controlled trial to compare the effect of lorazepam versus placebo as an adjuvant to haloperidol for persistent agitation in patients with delirium."	5.27	The minimal clinically important difference of the Richmond Agitation-Sedation Scale in patients with cancer with agitated delirium. ( Arthur, J; Bruera, E; Dalal, S; Dev, R; Dibaj, SS; Hess, K; Hui, D; Reddy, S, 2018)
"We present a novel study to determine whether ketamine is a rapid and safe option, compared to a combination of midazolam and haloperidol for the sedation of patients presenting to the ED with psychomotor agitation and violent behavior."	5.27	Rapid agitation control with ketamine in the emergency department (RACKED): a randomized controlled trial protocol. ( Andolfatto, G; Barbic, D; Barbic, SP; Grunau, B; Honer, WG; MacEwan, W; Scheuermeyer, FX; Wong, H, 2018)
"To compare the efficacy and safety of scheduled low-dose haloperidol versus placebo for the prevention of delirium (Intensive Care Delirium Screening Checklist ≥ 4) administered to critically ill adults with subsyndromal delirium (Intensive Care Delirium Screening Checklist = 1-3)."	5.22	Preventing ICU Subsyndromal Delirium Conversion to Delirium With Low-Dose IV Haloperidol: A Double-Blind, Placebo-Controlled Pilot Study. ( Al-Qadheeb, NS; Devlin, JW; Pacheco, MN; Roberts, RJ; Ruthazer, RR; Schumaker, G; Skrobik, Y, 2016)
"To evaluate the clinical effectiveness, safety, and cost of dexmedetomidine for the treatment of agitated delirium refractory to haloperidol in nonintubated critically ill patients."	5.22	Dexmedetomidine for the Treatment of Hyperactive Delirium Refractory to Haloperidol in Nonintubated ICU Patients: A Nonrandomized Controlled Trial. ( Baeza, N; Cabré, L; Calizaya, M; Carrasco, G; Gimeno, G; Manzanedo, D; Portillo, E, 2016)
" droperidol for patients with agitation and aggression."	5.20	Droperidol v. haloperidol for sedation of aggressive behaviour in acute mental health: randomised controlled trial. ( Calver, L; Drinkwater, V; Gupta, R; Isbister, GK; Page, CB, 2015)
" Acutely agitated patients with schizophrenia or schizoaffective disorder (n = 67) were randomized to receive 10 mg IM olanzapine (n = 37) or 5 mg IM haloperidol plus 2 mg IM lorazepam (n = 30)."	5.20	Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: An open-label, randomized controlled trial. ( Chen, HH; Chen, YH; Hsieh, MH; Huang, CL; Huang, GH; Hwang, TJ; Hwu, HG, 2015)
"Oral haloperidol, risperidone, and olanzapine seem to be suitable for treating acute severe psychotic agitation in schizophrenia spectrum disorders."	5.19	Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine. ( Abderhalden, C; Horn, H; Maier, N; Moggi, F; Moskvitin, K; Müller, TJ; Strik, W; Walther, S, 2014)
"This study was a comparative investigation of the clinical efficacy and safety of intramuscular (IM) olanzapine, IM haloperidol, and IM levomepromazine in acute agitated patients with schizophrenia."	5.19	A naturalistic comparison study of the efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular levomepromazine in acute agitated patients with schizophrenia. ( Gen, K; Suzuki, H; Takahashi, Y, 2014)
" Previous studies have demonstrated that IM ziprasidone is efficacious and safe for treatment of agitation in schizophrenia."	5.17	Intramuscular ziprasidone versus haloperidol for managing agitation in Chinese patients with schizophrenia. ( Deng, H; Gao, C; Karayal, ON; Li, K; Pan, S; Shi, J; Shu, L; Tang, H; Vanderburg, D; Wang, G; Wang, X; Xie, S; Xu, X; Zhang, H; Zhao, J, 2013)
"Patients were randomized into 2 groups; in group 1, patients received 5mg of haloperidol intramuscularly and in group 2, patients received 5mg of morphine sulfate intramuscularly to control delirium symptoms."	5.17	Morphine is a reasonable alternative to haloperidol in the treatment of postoperative hyperactive-type delirium after cardiac surgery. ( Akgün, S; Atalan, N; Başaran, C; Efe Sevim, M; Fazlıoğulları, O, 2013)
"This randomized, parallel-group, open study investigated the efficacy and safety of risperidone oral solution (RIS-OS) in combination with clonazepam and intramuscular haloperidol for the treatment of acute agitation in patients with schizophrenia, and the study explored the possibility of decreasing the efficacy of an acute 6-week treatment by switching intramuscular haloperidol injection to RIS-OS."	5.16	Comparison of risperidone oral solution and intramuscular haloperidol with the latter shifting to oral therapy for the treatment of acute agitation in patients with schizophrenia. ( Chen, H; Fang, M; Huang, J; Li, LH; Li, Y; Liu, L; Wang, B; Wang, G; Wu, R; Ye, M; Zhang, L; Zhang, Q; Zhao, JP; Zheng, H; Zhou, J; Zhu, S, 2012)
"All medications produced a calming effect within one hour of administration, but only olanzapine and haloperidol reduced agitation by less than 10 points, and only olanzapine reduced aggression by less than four points in the first hour."	5.15	Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone. ( Baldaçara, L; Cordeiro, DC; Jackoswski, AP; Sanches, M, 2011)
"Agitated delirium is common in patients undergoing mechanical ventilation, and is often treated with haloperidol despite concerns about safety and efficacy."	5.14	Dexmedetomidine vs. haloperidol in delirious, agitated, intubated patients: a randomised open-label trial. ( Ainslie, WR; Bates, S; Bellomo, R; Goldsmith, D; O'Sullivan, K; Reade, MC, 2009)
"In patients with early-episode schizophrenia, aripiprazole demonstrates greater improvement than haloperidol on PANSS items related to social functioning."	5.14	Effect of aripiprazole versus haloperidol on PANSS Prosocial items in early-episode patients with schizophrenia. ( Baker, RA; Docherty, JP; Eudicone, J; Mankoski, R; Marcus, RN; Mathew, S; McQuade, RD, 2010)
" This network meta-analysis aims to evaluate the efficacy of short-acting IM second-generation antipsychotic drugs, haloperidol and placebo in patients with diagnosis of schizophrenia and schizophrenia-like disorders that present acute agitation."	5.12	Short-acting intramuscular second-generation antipsychotic drugs for acutely agitated patients with schizophrenia spectrum disorders. A systematic review and network meta-analysis. ( Bighelli, I; Davis, JM; Deste, G; Leucht, S; Paris, G; Schneider-Thoma, J; Siafis, S; Vita, A; Zhu, Y, 2021)
"The goal of this study was to compare the efficacy and safety of olanzapine versus haloperidol in the treatment of agitation and aggression in patients with dementia."	5.12	Olanzapine versus haloperidol in the treatment of agitation in elderly patients with dementia: results of a randomized controlled double-blind trial. ( Lousberg, R; Verhey, FR; Verkaaik, M, 2006)
"When comparing treatment effects on individual symptoms frequently occurring in patients with dementia, risperidone significantly improved symptoms of agitation, wandering, diurnal rhythm disturbance and anxieties, among other symptoms, compared with haloperidol."	5.12	Comparative efficacy of risperidone versus haloperidol on behavioural and psychological symptoms of dementia. ( Choi, SK; Greenspan, AJ; Suh, GH, 2006)
"This double-blind, placebo-controlled study investigated the efficacy and safety of intramuscular (IM) aripiprazole and IM haloperidol for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder."	5.12	Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. ( Andrezina, R; Carson, WH; Iwamoto, T; Josiassen, RC; Manos, G; Marcus, RN; Oren, DA; Stock, E, 2006)
"Intramuscular aripiprazole is effective in patients with acute agitation associated with schizophrenia, comparable to IM haloperidol, and enables convenient transfer to oral aripiprazole therapy."	5.12	Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study. ( Andrezina, R; Carson, WH; Manos, G; Marcus, RN; McQuade, RD; Oren, DA; Stock, E, 2006)
"Acutely agitated patients with schizophrenia or schizoaffective disorder treated with aripiprazole IM or haloperidol IM demonstrated similar effective and safe transition to their respective oral formulations."	5.12	Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations. ( Allen, MH; Crandall, DT; Currier, GW; Daniel, DG; Manos, G; McQuade, R; Oren, D; Pikalov, AA; Zimbroff, DL, 2007)
"We conducted a prospective double-blind study of accelerated dose titration of olanzapine in the treatment of newly admitted acutely agitated patients with schizophrenia."	5.11	Efficacy of accelerated dose titration of olanzapine with adjunctive lorazepam to treat acute agitation in schizophrenia. ( Ahl, J; Kinon, BJ; McMullen, E; Rotelli, MD, 2004)
" In 3 double-blind studies, acutely agitated patients with schizophrenia (N = 311), bipolar mania (N = 201), or dementia (N = 206) were treated with intramuscular (1-3 injections/24 hrs) olanzapine (2."	5.10	Calming versus sedative effects of intramuscular olanzapine in agitated patients. ( Alaka, K; Battaglia, J; Lindborg, SR; Meehan, K; Wright, P, 2003)
" Databases included: placebo-controlled [two schizophrenia, one bipolar mania trials (n=565)]; haloperidol-controlled [two schizophrenia trials (n=482)]; geriatric placebo-controlled [1 dementia trial (n=204)]."	5.10	Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients. ( Alaka, K; Beasley, CM; Lindborg, SR; Taylor, CC, 2003)
" Midazolam was more rapidly sedating than haloperidol-promethazine, reducing the time people are exposed to aggression."	5.10	Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. ( , 2003)
"An intramuscular (IM) formulation of olanzapine has been developed because there are no rapid-acting IM atypical antipsychotic drugs currently available in the United States for treating acute agitation in patients with schizophrenia."	5.10	A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. ( Birkett, M; Breier, A; Brook, S; David, S; Dossenbach, M; Ferchland, I; Kiesler, G; Meehan, K; Palmer, R; Sutton, V; Taylor, CC; Wright, P, 2002)
"The authors evaluated the comparative efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular placebo for the treatment of acute agitation in schizophrenia."	5.09	Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. ( Alaka, KJ; Bernardo, M; Birkett, M; Bradley, P; Breier, A; David, SR; Ferchland, I; Krueger, J; Meehan, K; Reinstein, M; San, L; Saunders, JC; Wright, P, 2001)
"The authors compared the efficacy and side effects of trazodone and haloperidol for treating agitated behaviors associated with dementia."	5.08	A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. ( Berisford, MA; Gray, KF; Gunay, I; Mahler, ME; Sultzer, DL, 1997)
"For the 60 patients who completed phase A, standard-dose haloperidol was efficacious and superior to both low-dose haloperidol and placebo for scores on the Brief Psychiatric Rating Scale psychosis factor and on psychomotor agitation."	5.08	A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. ( Bell, K; Cooper, TB; Devanand, DP; Marder, K; Mayeux, R; Michaels, KS; Pelton, GH; Sackeim, HA; Sullivan, MA, 1998)
"We now present data from a randomized, double-blind clinical study of lorazepam versus haloperidol in 20 hospitalized patients with a DSM-III-R diagnosis of bipolar disorder who were being treated concomitantly with lithium."	5.07	Adjunctive treatment of manic agitation with lorazepam versus haloperidol: a double-blind study. ( Creelman, WL; Lenox, RH; Newhouse, PA; Whitaker, TM, 1992)
"Fifty-nine elderly residents of long-term care facilities who had DSM-III diagnoses of dementia were studied in an 8-week randomized, double-blind comparison trial of haloperidol, oxazepam, and diphenhydramine to test the efficacy of these agents in the treatment of clinically significant behavioral disturbances in patients with dementia."	5.06	Pharmacologic treatment of noncognitive behavioral disturbances in elderly demented patients. ( Coccaro, EF; Duvvi, K; Giordani, B; Kramer, E; Nora, R; Patel, BM; Rice, CM; Thorne, A; Torres, J; Zemishlany, Z, 1990)
" Haloperidol has a relatively weak effect on aggression when given alone and can also cause side effects such as early dyskinesia and epileptic seizures."	5.01	The Use of Rapid Tranquilization in Aggressive Behavior. ( Hirsch, S; Steinert, T, 2019)
"To evaluate the effects of intramuscular aripiprazole in the treatment of psychosis-induced aggression or agitation (rapid tranquillisation)."	4.98	Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation). ( Jajawi, S; Jayaram, MB; Ostinelli, EG; Sayal, K; Spyridi, S, 2018)
"Haloperidol used alone is recommended to help calm situations of aggression or agitation for people with psychosis."	4.95	Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation). ( Adams, CE; Brooke-Powney, MJ; Li, X; Ostinelli, EG, 2017)
"To examine whether haloperidol plus promethazine is an effective treatment for psychosis-induced aggression."	4.93	Haloperidol plus promethazine for psychosis-induced aggression. ( Alexander, J; Allen, MH; Gandhi, P; Huf, G, 2016)
"Haloperidol, used alone is recommended to help calm situations of aggression with people with psychosis."	4.88	Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation). ( Adams, CE; Jones, H; Powney, MJ, 2012)
"The objective of this article is to assess the clinical characteristics of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder receiving aripiprazole, haloperidol, olanzapine, or placebo."	4.86	Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials. ( Assunção-Talbott, S; Barnes, TR; Buckley, P; Correll, CU; Eudicone, J; Kane, JM; McQuade, R; Pikalov, A; Sachs, G; Tran, QV, 2010)
"To examine the effects of oral or intramuscular chlorpromazine for psychosis induced agitation or aggression."	4.86	Chlorpromazine for psychosis induced aggression or agitation. ( Adams, CE; Ahmed, U; Jones, H, 2010)
"Haloperidol, which is commonly used to treat agitation in critically ill patients, has been associated with the development of neuroleptic malignant syndrome (NMS)."	4.85	Neuroleptic malignant syndrome in traumatic brain injury patients treated with haloperidol. ( Bellamy, CJ; Falcione, BA; Kane-Gill, SL; Seybert, AL, 2009)
"To examine whether haloperidol plus promethazine is an effective treatment for psychosis induced agitation/aggression."	4.85	Haloperidol plus promethazine for psychosis-induced aggression. ( Alexander, J; Allen, MH; Huf, G; Raveendran, NS, 2009)
"To examine whether haloperidol plus promethazine is an effective treatment for psychosis induced agitation/aggression."	4.82	Haloperidol plus promethazine for psychosis induced aggression. ( Alexander, J; Allen, MH; Huf, G, 2005)
"The CDCIG Specialized Register was searched to identify all available reports on haloperidol treatment of agitated dementia."	4.81	Haloperidol for agitation in dementia. ( Colford, J; Lonergan, E; Luxenberg, J, 2001)
" Evidence suggests that haloperidol was useful in the control of aggression, but was associated with increased side effects; there was no evidence to support the routine use of this drug for other manifestations of agitated dementia."	4.81	Haloperidol for agitation in dementia. ( Colford, J; Lonergan, E; Luxenberg, J, 2002)
"To study the efficacy and safety of intranasal administration of 5 mg haloperidol on mild-moderate agitated patients with schizophrenia or schizoaffective disorder in an acute psychiatry unit setting."	4.02	Efficacy and safety of intranasal haloperidol in an acute Psychiatry Unit: a pilot study on schizophrenic patients with mild-modedate agitation. ( Duñó Ambròs, R; Iglesias-Lepine, ML; Labad Arias, J; Monreal Ortiz, JAMO; Oliva Morera, JC; Palao Vidal, D, 2021)
" When the diagnosis of haloperidol-induced acute dystonia was made, 3 mg of intravenous biperiden was promptly administered with complete clinical resolution in 15 min."	3.91	Involuntary movements in an adolescent: what are the causes? ( Brito, N; Fernandes, A; Moura, L; Vaz, AS, 2019)
"Over 67 days, 1,461 patients were screened in the ED, 269 had bipolar I or schizophrenia, 194 of whom had a contraindication to inhaled loxapine leaving 75 eligible patients; preconsent was obtained in 43 patients."	3.91	Study Enrollment When "Preconsent" Is Utilized for a Randomized Clinical Trial of Two Treatments for Acute Agitation in the Emergency Department. ( Cole, JB; Driver, BE; Klein, LR; Mullinax, SZ; Nordstrom, KD; Wilson, MP, 2019)
"The World Health Organization recommends that anxiety, depression, agitation and delirium at end of life should be treated with drugs such as lorazepam, diazepam, midazolam and haloperidol."	3.83	Look again at psychedelic drugs. ( Cameron, R, 2016)
"Completion of a survey containing 10 hypothetical ICU cases in which patients had agitated delirium for which a psychiatrist recommended intravenous haloperidol 5 mg every 6 hours."	3.79	Agreement between ICU clinicians and electrophysiology cardiologists on the decision to initiate a QTc-interval prolonging medication in critically ill patients with potential risk factors for torsade de pointes: a comparative, case-based evaluation. ( Al-Qadheeb, NS; Devlin, JW; Estes, NA; Fongemie, JM; Roberts, RJ; Ruthazer, R; Temtanakitpaisan, Y, 2013)
"Practice guidelines recommend the use of low dose haloperidol when medication is needed to treat delirium with acute agitation in hospitalized older people."	3.79	Haloperidol overdosing in the treatment of agitated hospitalized older people with delirium: a retrospective chart review from a community teaching hospital. ( Dorokhine, I; Knapp, CM; Musuku, M; Patel, N; Zirker, W, 2013)
"To compare the effectiveness of intramuscular (IM) olanzapine and typical IM antipsychotics in naturalistically treated acutely agitated patients with schizophrenia or acute mania."	3.75	Intramuscular olanzapine versus short-acting typical intramuscular antipsychotics: comparison of real-life effectiveness in the treatment of agitation. ( Castle, DJ; Isik, T; Karagianis, J; Kim, CY; Melamed, Y; Omar, AN; Pidrman, V; Rosales, JI; Sarosi, A; Treuer, T; Udristoiu, T, 2009)
"Analysis 1 found that nonsedated patients with bipolar I disorder and schizophrenia showed significant decreases in PEC scores following treatment with aripiprazole IM (p < 0."	3.74	Intramuscular aripiprazole in the control of agitation. ( Citrome, LL; Crandall, DT; Currier, GW; Manos, G; McQuade, R; Oren, D; Pikalov, AA; Zimbroff, DL, 2007)
"The authors report a case of a patient, who in a few days after an abrupt discontinuation of clozapine and haloperidol developed agitated and confused state resembling neuroleptic malignant syndrome (NMS) and clozapine withdrawal symptoms at the same time."	3.73	Neuroleptic malignant syndrome and clozapine withdrawal at the same time? ( Aukst-Margetić, B; Margetić, B, 2005)
"Medical records were reviewed retrospectively to identify consecutive patients who were admitted to our neuropsychiatry service with the presenting complaint of dementia (DSM-IV) with agitation and who were given intramuscular ziprasidone and then administered an electrocardiogram (ECG) (N = 23)."	3.73	A retrospective study of the safety of intramuscular ziprasidone in agitated elderly patients. ( Brown, FW; Greco, KE; Tune, LE; Van Horn, WA, 2005)
"This post hoc analysis used data from a multinational, double-blind, randomized, placebo-controlled study comparing the efficacy of olanzapine, haloperidol, and placebo in acutely agitated inpatients aged > or =18 years with schizophrenia conducted at hospitals in 13 countries."	3.73	A post hoc analysis of transitioning to oral treatment with olanzapine or haloperidol after 24-hour intramuscular treatment in acutely agitated adult patients with schizophrenia. ( Ahl, J; Battaglia, J; Houston, JP; Kaiser, CJ; Meyers, AL, 2005)
"This reanalysis of a previously reported pivotal clinical trial assessed whether quetiapine or haloperidol has benefits for the treatment of hostility and agitation among patients experiencing an acute exacerbation of schizophrenia."	3.72	A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia. ( Chengappa, KN; Goldstein, JM; Greenwood, M; John, V; Levine, J, 2003)
" Administration of large intravenous doses of haloperidol was necessary for control of psychomotor agitation due to delirium."	3.70	Torsades de pointes secondary to intravenous haloperidol after coronary bypass grafting surgery. ( Bélisle, S; Carrier, M; Cartier, R; Denault, AY; Perrault, LP, 2000)
"We report on three patients with acute coronary syndromes who developed QT interval prolongation associated with intravenous haloperidol use."	3.70	Corrected QT interval prolongation associated with intravenous haloperidol in acute coronary syndromes. ( Block, PC; Douglas, PH, 2000)
"A case of agitated delirium secondary to bilateral occipital cerebral infarctions in a cancer patient was refractory to trials of large doses of intravenous psychotropic agents, but continuous intravenous infusion of haloperidol controlled agitation rapidly and safely."	3.67	Treatment of severe, refractory agitation with a haloperidol drip. ( Adams, F; Fernandez, F; Holmes, VF; Kavanaugh, JJ, 1988)
" This constellation of symptoms, known as the neuroleptic malignant syndrome (NMS), partially improved when the neuroleptic medication was stopped, but complete resolution of the syndrome did not occur until the patient was treated with bromocriptine."	3.67	Neuroleptic malignant syndrome complicating closed head injury. ( Van Haren, J; Vincent, FM; Zimmerman, JE, 1986)
"The phenomenon of restlessness, agitation, or cognitive disturbances experienced by dying patients is well-known in palliative care; more than half of these patients will experience delirium symptoms at end-of-life."	3.11	An open-label clinical trial of oral transmucosal haloperidol and oral transmucosal olanzapine in the treatment of terminal delirium at home. ( Chong, PH; Kan, AD; Koh, YH; Lin, K; Lyu, XJ; Yeo, ZZ, 2022)
" For 80 patients treated with sodium valproate, the mean ± SD dosage was 1541."	2.80	Efficacy and safety of valproic acid versus haloperidol in patients with acute agitation: results of a randomized, double-blind, parallel-group trial. ( Asadollahi, S; Azadbakht, A; Hatamabadi, H; Heidari, K; Mirmohseni, L; Vafaee, R; Yunesian, S, 2015)
" Both groups reported insomnia as the most common treatment-emergent adverse event, and no serious adverse event was reported."	2.79	A double-blind, randomized comparison study of efficacy and safety of intramuscular olanzapine and intramuscular haloperidol in patients with schizophrenia and acute agitated behavior. ( Chan, HY; Chen, CK; Chen, JJ; Chen, YS; Chou, SY; Ree, SC; Su, LW, 2014)
"Suicidal ideation was significantly associated with clinician observed akathisia, depressed mood, younger age, and use of propranolol."	2.77	Akathisia and suicidal ideation in first-episode schizophrenia. ( Gaebel, W; Gastpar, M; Heuser, I; Jäger, M; Klingenberg, S; Klosterkötter, J; Lewitzka, U; Maier, W; Mayr, A; Möller, HJ; Musil, R; Ohmann, C; Riedel, M; Schennach, R; Schlösser, R; Schmitt, A; Schneider, F; Seemüller, F, 2012)
"Haloperidol open treatment was efficacious, and relapse was greater on placebo than with haloperidol continuation."	2.76	A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease. ( Cunqueiro, K; Devanand, DP; Marder, K; Pelton, GH; Sackeim, HA, 2011)
" Dosage was increased stepwise from 100mg up to 400mg trimipramine and from 100mg up to 200mg amitriptyline combined with 2mg up to 7."	2.74	Outcome in delusional depression comparing trimipramine monotherapy with a combination of amitriptyline and haloperidol--a double-blind multicenter trial. ( Ackl, N; Hatzinger, M; Held, K; Holsboer, F; Holsboer-Trachsler, E; Ising, M; Kaschka, W; Kasper, S; Konstantinidis, A; Künzel, HE; Sonntag, A; Steiger, A; Uhr, M; Yassouridis, A, 2009)
"Lorazepam alone was as effective as lorazepam plus haloperidol or lorazepam plus risperidone in this small trial."	2.72	Risperidone versus haloperidol, in combination with lorazepam, in the treatment of acute agitation and psychosis: a pilot, randomized, double-blind, placebo-controlled trial. ( Currier, GW; McMullan, JT; Veser, BD; Veser, FH; Zealberg, J, 2006)
"The authors conducted a multicenter, double-blind, placebo-controlled, randomized trial of flexibly dosed quetiapine and haloperidol."	2.72	Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. ( Copenhaver, M; Katz, IR; Mintzer, JE; Schneider, L; Street, J; Tariot, PN; Williams-Hughes, C, 2006)
" Mean score improvements at 30, 60, and 120 minutes after dosing were significant at each timepoint in both groups (p <."	2.71	Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. ( Bossie, CA; Chou, JC; Currier, GW; Feifel, D; Gharabawi, GM; Mahmoud, RA; Turkoz, I, 2004)
"Ziprasidone i."	2.71	The tolerability of intramuscular ziprasidone and haloperidol treatment and the transition to oral therapy. ( Daniel, DG; Harrigan, EP; Swift, RH; Zimbroff, DL, 2004)
"Midazolam has a significantly shorter time to onset of sedation and a more rapid time to arousal than lorazepam or haloperidol."	2.71	A prospective, double-blind, randomized trial of midazolam versus haloperidol versus lorazepam in the chemical restraint of violent and severely agitated patients. ( Dresden, GM; Levitt, MA; Nobay, F; Simon, BC, 2004)
"In olanzapine-treated patients, improvement in BPRS agitation and positive symptom scores was significantly greater at weeks 4, 5, and 6 (agitation scores, p < or = ."	2.70	Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia. ( Hill, AL; Kinon, BJ; Milton, DR; Roychowdhury, SM, 2001)
"Carbamazepine has been reported to decrease agitation associated with various psychiatric disorders and to reduce neuroleptic side effects."	2.68	Effect of carbamazepine on agitation in Alzheimer's inpatients refractory to neuroleptics. ( Lemke, MR, 1995)
"clonazepam is an effective, safe, but slower-acting alternative to I."	2.67	A double-blind randomized clinical trial of rapid tranquilization with I.M. clonazepam and I.M. haloperidol in agitated psychotic patients with manic symptoms. ( Annable, L; Chouinard, G; Holobow, N; Szkrumelak, N; Turnier, L, 1993)
"During long-term treatment of schizophrenia with antipsychotic medication, side effects such as weight gain and tardive dyskinesia may develop, while other extrapyramidal side effects may continue."	2.67	Side effects during long-term treatment with depot antipsychotic medication. ( Cookson, JC, 1991)
"The target symptom is psychomotor agitation."	2.65	[Comparative study of the effects of sultopride and haloperidol in agitation states. 94 cases at the psychiatric infirmary of the Paris police headquarters]. ( Anguera, P; Bulteau, J; Soubrier, JP, 1983)
"We studied the incidence of akathisia in two populations of newly admitted schizophrenic patients: one group was treated with haloperidol and the other group was treated with thiothixene hydrochloride."	2.65	Akathisia with haloperidol and thiothixene. ( Marder, SR; May, PR; Van Putten, T, 1984)
"A randomized cross-over trial was conducted in 30 restless mentally subnormal patients by increasing the dosage of haloperidol from 10 to 60 mg and that of thioridazine from 100 to 600 mg daily."	2.65	Haloperidol, thioridazine and placebo in mentally subnormal patients-serum levels and clinical effects. ( Räisänen, P; Rimón, R; Väisänen, K; Viukari, M, 1981)
", as needed over a four-hour period (total dosage ranging from 4 to 32 mg."	2.64	Relative efficacy of parenteral haloperidol and thiothixene for the emergency treatment of acutely excited and agitated patients. ( Stotsky, BA, 1977)
"Based on findings from 34 blinded, randomized controlled trials, common acute adverse effects of second-generation antipsychotics and haloperidol were headache, dizziness, insomnia, and somnolence."	2.58	Evidence-Based Review Of Pharmacotherapy For Acute Agitation. Part 2: Safety. ( Zun, LS, 2018)
"When droperidol was compared with placebo, for the outcome of tranquillisation or asleep by 30 minutes we found evidence of a clear difference (1 RCT, N = 227, RR 1."	2.53	Droperidol for psychosis-induced aggression or agitation. ( Khokhar, MA; Rathbone, J, 2016)
"When haloperidol and midazolam were compared with olanzapine, there was some evidence the combination was superior in terms of improvement, sedation and behaviour."	2.49	Benzodiazepines for psychosis-induced aggression or agitation. ( Beck, A; Gillies, D; Rathbone, J; Sampson, S, 2013)
"Delirium is one of the most serious and common complications that up to one third of older patients admitted to hospital develop."	2.48	Confusion, agitation and delirium. ( Martin, JJ, 2012)
"Children with Sydenham's chorea and PANDAS (Pediatric autoimmune neuropsychiatric disorders associated with streptococcal throat infections) share an array of neuropsychiatric symptoms and distinguishing one from the other, especially at onset can prove challenging."	2.42	Distinguishing PANDAS from Sydenham's chorea: case report and review of the literature. ( Schoeman, JF; van Toorn, R; Weyers, HH, 2004)
"Neuroleptic malignant syndrome is a rare complication of antipsychotic medications."	2.39	Neuroleptic malignant syndrome in a trauma patient. ( Burke, C; Castellano, J; Fulda, GJ, 1995)
" Secondary outcomes include comparison of length of stay, utilization of restraints, and discharge outcomes between dosage groups."	1.91	Optimal Injectable Haloperidol Dose Assessment in the Older Hospitalized Inpatient. ( Bhatti, H; Brenner, JM; Britton, S; Noviasky, J; Yuksel, JM, 2023)
"Tardive akathisia is a movement disorder characterized by internal restlessness with an uncontrollable urge to move, leading to repetitive movements."	1.91	Acetaminophen improves tardive akathisia induced by dopamine D ( Kaneko, S; Nagaoka, K; Nagayasu, K; Shirakawa, H, 2023)
" No significant differences were found in the rate of violent behavior and antipsychotic dosage at discharge."	1.72	Olanzapine intramuscular shows better efficacy than zuclopenthixol acetate intramuscular in reducing the need for restraint, but not in comparison to haloperidol intramuscular. ( Bloemhof-Bris, E; Shelef, A; Sinai, O; Stryjer, R; Weizman, S, 2022)
"As its name suggests, delirious mania presents as a mixture of hyperactive delirium and mania; additional features may include psychosis, autonomic activation, and catatonia."	1.62	Pseudodelirium: Psychiatric Conditions to Consider on the Differential for Delirium. ( Ainsworth, A; Andrews, P; Ely, EW; Oldham, MA; Roy, K; Wilson, JE, 2021)
"Ketamine is an emerging drug for the treatment of acute undifferentiated agitation in the prehospital environment, however no prospective comparative studies have evaluated its effectiveness or safety in this clinical setting."	1.43	A prospective study of ketamine versus haloperidol for severe prehospital agitation. ( Bache-Wiig, P; Cole, JB; Engebretsen, KM; Fryza, BJ; Ho, JD; Kornas, RL; Moore, JC; Nystrom, PC; O'Brien-Lambert, A; Orozco, BS; Steinberg, LW; Stellpflug, SJ, 2016)
"Bilateral intraocular pressures were monitored before and after the first 7 ECTs and intermittently after ECT for 10 months of maintenance ECT."	1.40	Stability of intraocular pressure after retinal reattachment surgery during electroconvulsive therapy for intractable self-injury in a 12-year-old autistic boy. ( Reti, IM; Wachtel, LE; Ying, H, 2014)
"Agitated delirium is a palliative care emergency."	1.40	High-dose neuroleptics and neuroleptic rotation for agitated delirium near the end of life. ( Bascom, PB; Bordley, JL; Lawton, AJ, 2014)
"Animal work on the behavioral effects of antipsychotic treatment suggests that different dosing regimens could affect drug sensitivity differently, with an intermittent treatment regimen tending to cause a sensitization effect, while a continuous treatment causing a tolerance."	1.40	Differential effects of intermittent versus continuous haloperidol treatment throughout adolescence on haloperidol sensitization and social behavior in adulthood. ( Gao, J; Li, M, 2014)
"Ziprasidone was associated with a shorter LOS compared with olanzapine, 13."	1.37	Comparison of short-acting intramuscular antipsychotic medication: impact on length of stay and cost. ( Benedetti, AM; Frazee, LA; Leung, JG; Myers, N, 2011)
"The literature on akathisia in pediatric patients, and especially in patients following acute head injury, is reviewed, with suggestions for an approach to these symptoms in this clinical setting."	1.36	Akathisia after mild traumatic head injury. ( Desai, A; Duhaime, AC; Nierenberg, DW, 2010)
"Five days after surgery, Neuroleptic Malignant Syndrome was diagnosed."	1.35	Neuroleptic malignant syndrome and cardiac surgery. A case report. ( Sirois, F, 2008)
" These data indicate that chronic administration of RISP and HAL impede behavioral recovery after TBI and impair performance in uninjured controls."	1.35	Chronic administration of antipsychotics impede behavioral recovery after experimental traumatic brain injury. ( Cheng, JP; Hoffman, AN; Kline, AE; Massucci, JL; Zafonte, RD, 2008)
"Delirium is a common, underdiagnosed and serious problem in intensive care unit patients."	1.35	Tackling agitated delirium--the tip of the iceberg. ( Page, VJ, 2009)
"All four of the reviewed cases with myokymia of the shoulders were intubated and none without it were intubated."	1.35	Fasciculations after rattlesnake envenomations: a retrospective statewide poison control system study. ( Cantrell, FL; Vohra, R; Williams, SR, 2008)
"Haloperidol was associated with significantly lower hospital mortality."	1.33	Haloperidol use is associated with lower hospital mortality in mechanically ventilated patients. ( Angus, DC; Clermont, G; Fink, MP; Kersten, A; Kong, L; Milbrandt, EB; Weissfeld, LA, 2005)
" Carbamazepine at a dosage of 800 mg daily was the most effective medication used."	1.33	Auditory hallucinations after right temporal gyri resection. ( Brennan, DM; Stewart, B, 2005)
"ziprasidone for the treatment of acute agitation."	1.33	Naturalistic study of intramuscular ziprasidone versus conventional agents in agitated elderly patients: retrospective findings from a psychiatric emergency service. ( Francis, A; Kohen, I; Preval, H; Southard, R, 2005)
"Neuroleptic malignant syndrome is a rare disorder that manifests with hyperthermia, muscle rigidity and autonomic instability."	1.32	Early recognition of neuroleptic malignant syndrome during traumatic brain injury rehabilitation. ( Colachis, SC; Depalma, MJ; Kadyan, V; Mysiw, WJ; Sanderson, JD, 2003)
"Haloperidol was administered more often to elderly patients (p=0."	1.31	Frequency, severity, and treatment of agitation in young versus elderly patients in the ICU. ( Berthiaume, D; Fraser, GL; Prato, BS; Riker, RR; Wilkins, ML, 2000)
"Oral treatment with risperidone and lorazepam appears to be a tolerable and comparable alternative to intramuscular haloperidol and lorazepam for short-term treatment of agitated psychosis in patients who accept oral medications."	1.31	Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. ( Currier, GW; Simpson, GM, 2001)
"Haloperidol was abruptly shifted to risperidone 0."	1.31	Shifting from haloperidol to risperidone for behavioral disturbances in dementia: safety, response predictors, and mood effects. ( Chang, WH; Chang, YC; Chiu, CC; Huang, MC; Lane, HY; Su, MH, 2002)
"Pretreatment with propranolol (5 mg/kg) reduced the number of Fos-positive nuclei in the cingulate cortex area 3, the piriform cortex and area 1 of the parietal cortex."	1.30	Propranolol attenuates haloperidol-induced Fos expression in discrete regions of rat brain: possible brain regions responsible for akathisia. ( Fujiwara, Y; Hamamura, T; Kuroda, S; Lee, Y; Ohashi, K, 1998)
"Haloperidol 0."	1.28	Brachial plexus palsy with the use of haloperidol and a geriatric chair. ( King, T; Mallet, L, 1991)
"Haloperidol was implicated in 47 patients (37%), followed by amitriptyline/perphenazine in 30%, thioridazine in 27%, and chlorpromazine in 20%."	1.28	Neurologic approach to drug-induced movement disorders: a study of 125 patients. ( Jankovic, J; Miller, LG, 1990)
" An increase in dosage also had only a transient effect."	1.27	Development of tolerance to the therapeutic effect of amantadine on akathisia. ( Barreira, P; Lipinski, JF; Zubenko, GS, 1984)
"The mean plasma cortisol level of the akathisia group was tended to be lower than that of the non-akathisia group."	1.27	[Biochemical and psychophysiological study of haloperidol-induced akathisia]. ( Odo, S, 1983)
"Akathisia is a common but frequently unrecognized complication of antipsychotic medication."	1.27	Akathisia: the syndrome of motor restlessness. ( Friedman, JH; Wagner, RL, 1987)
"Two agitated patients with Alzheimer's disease who either failed to respond or worsened with conventional low-dose neuroleptic and other pharmacologic treatment are described."	1.27	Very low-dose neuroleptic treatment in two patients with agitation associated with Alzheimer's disease. ( Cubberley, L; Lampe, TH; Risse, SC, 1987)
"Variables measured included length of coma, PTA, rehabilitation admission and discharge functional status, and CT scan results."	1.27	Agitation in closed head injury: haloperidol effects on rehabilitation outcome. ( Jellinek, HM; Rao, N; Woolston, DC, 1985)
"A patient with neuroleptic-induced akathisia was successfully treated with a combination of baclofen (a GABA agonist) and clonazepam (a serotonergic agent)."	1.27	Successful treatment of neuroleptic-induced akathisia with baclofen and clonazepam. A case report. ( Sandyk, R, 1985)
"Akathisia is an easily treatable but often overlooked extrapyramidal symptom induced by neuroleptic drugs."	1.26	Akathisia: an overlooked, distressing, but treatable condition. ( Shen, WW, 1981)
"Agitated patients with organic brain disorders represent relatively common diagnostic and management problems."	1.26	Treatment of the agitated patient with an organic brain disorder. ( Fauman, MA, 1978)

Research

Studies (248)

Authors

Clinical Trials (23)

Trial Overview

Trial Outcomes

Change in RASS Score (0-30 Minutes)

Timeframe	Studies, this research(%)	All Research%
pre-1990	39 (15.73)	18.7374
1990's	31 (12.50)	18.2507
2000's	79 (31.85)	29.6817
2010's	76 (30.65)	24.3611
2020's	23 (9.27)	2.80

Authors	Studies
Talaga, P	1
Matagne, A	1
Klitgaard, H	1
Duñó Ambròs, R	1
Oliva Morera, JC	1
Iglesias-Lepine, ML	1
Palao Vidal, D	1
Monreal Ortiz, JAMO	1
Labad Arias, J	1
Conrardy, MJ	1
Tyler, DJ	1
Cruz, DS	1
Fant, AL	1
Malik, S	1
Lank, PM	1
Kim, HS	1
Sinai, O	1
Stryjer, R	1
Bloemhof-Bris, E	1
Weizman, S	1
Shelef, A	1
Yan, VKC	1
Haendler, M	1
Lau, H	1
Li, X	2
Lao, KSJ	1
Tsui, SH	1
Yap, CYL	1
Knapp, MRJ	1
Chan, EW	1
Thiemann, P	1
Roy, D	1
Huecker, M	1
Senn, J	1
Javed, J	1
Thomas, A	1
Shreffler, J	1
Shaw, I	1
Jeffers, T	1
Darling, B	1
Edwards, C	1
Vadiei, N	1
Coralic, Z	1
Rader, ES	1
Vinson, DR	1
Wilson, MP	3
Lyu, XJ	1
Kan, AD	1
Chong, PH	1
Lin, K	1
Koh, YH	1
Yeo, ZZ	1
Stetson, SR	1
Osser, DN	2
Yuksel, JM	1
Brenner, JM	1
Britton, S	1
Bhatti, H	1
Noviasky, J	1
Kennedy, JM	1
Kunzler, NM	1
Hayes, BD	1
Lentz, SA	1
Walsh, K	1
Long, B	1
Nagaoka, K	2
Nagayasu, K	2
Shirakawa, H	2
Kaneko, S	2
Allen, PJ	1
Johanson, KE	1
Reveles, KR	1
Neff, LA	1
Lock, AE	1
Minami, T	1
Watanabe, H	1
Kato, T	1
Ikeda, K	2
Ueno, K	1
Matsuyama, A	1
Maeda, J	1
Sakai, Y	1
Harada, H	1
Kuriyama, A	1
Yamaji, K	1
Kitajima, N	1
Kamei, J	1
Takatani, Y	1
Sato, Y	1
Yamashita, Y	1
Mizota, T	1
Ohtsuru, S	1
Hirsch, S	1
Steinert, T	1
Vaz, AS	1
Brito, N	1
Moura, L	1
Fernandes, A	1
Lin, J	1
Figuerado, Y	1
Montgomery, A	1
Lee, J	1
Cannis, M	1
Norton, VC	1
Calvo, R	1
Sikand, H	1
Hui, D	3
De La Rosa, A	1
Wilson, A	1
Nguyen, T	1
Wu, J	1
Delgado-Guay, M	1
Azhar, A	1
Arthur, J	2
Epner, D	1
Haider, A	1
De La Cruz, M	1
Heung, Y	1
Tanco, K	1
Dalal, S	2
Reddy, A	1
Williams, J	1
Amin, S	1
Armstrong, TS	1
Breitbart, W	1
Bruera, E	3
Dib, JE	1
Yaacoub, HE	1
Ikdais, WH	1
Atallah, E	1
Merheb, TJ	1
Ajaltouni, J	1
Akkari, M	1
Mourad, M	1
Nasr, ME	1
Hachem, D	1
Kazour, F	1
Tahan, F	1
Haddad, G	1
Azar, J	1
Zoghbi, M	1
Haddad, C	1
Hallit, S	1
Adams, CE	9
Paris, G	1
Bighelli, I	1
Deste, G	1
Siafis, S	1
Schneider-Thoma, J	1
Zhu, Y	1
Davis, JM	1
Vita, A	1
Leucht, S	1
Scudamore, T	1
Liem, A	1
Wiener, M	1
Ekure, NS	1
Botash, C	1
Empey, D	1
Leontieva, L	1
Tang, M	1
Chen, M	1
Barbic, D	2
Andolfatto, G	2
Grunau, B	2
Scheuermeyer, FX	2
Macewan, B	1
Qian, H	1
Wong, H	2
Barbic, SP	2
Honer, WG	2
Wilson, JE	1
Andrews, P	1
Ainsworth, A	1
Roy, K	1
Ely, EW	1
Oldham, MA	1
Ostinelli, EG	2
Brooke-Powney, MJ	1
Jajawi, S	1
Spyridi, S	1
Sayal, K	1
Jayaram, MB	1
Zun, LS	2
Hess, K	1
Dibaj, SS	1
Dev, R	1
Reddy, S	1
Schildmann, E	1
Pörnbacher, S	1
Kalies, H	1
Bausewein, C	1
Edlinger, M	1
Welte, AS	1
Yalcin-Siedentopf, N	1
Kemmler, G	1
Neymeyer, F	1
Fleischhacker, WW	1
Hofer, A	1
Cole, JB	5
Klein, LR	4
Martel, ML	3
Driver, BE	3
Miner, JR	1
Hessel, M	1
Collins, JD	1
Horton, GB	1
Fagerstrom, E	1
Satpathy, R	1
Bao, GC	1
Bleimeister, IH	1
Zimmerman, LA	1
Wellcome, JL	1
Niesman, PJ	1
Radabaugh, HL	1
Bondi, CO	1
Kline, AE	2
MacEwan, W	1
Mullinax, SZ	1
Nordstrom, KD	1
Bak, M	1
Weltens, I	1
Bervoets, C	1
De Fruyt, J	1
Samochowiec, J	1
Fiorillo, A	1
Sampogna, G	1
Bienkowski, P	1
Preuss, WU	1
Misiak, B	1
Frydecka, D	1
Samochowiec, A	1
Bak, E	1
Drukker, M	1
Dom, G	1
Horton, G	1
Scharber, S	1
Ingravallo, F	1
de Nooijer, K	1
Pucci, V	1
Casini, C	1
Miccinesi, G	1
Rietjens, JAC	1
Morino, P	1
Elbakary, NAH	1
Ouanes, S	1
Zhang, H	1
Wang, G	2
Zhao, J	1
Xie, S	1
Xu, X	1
Shi, J	1
Deng, H	1
Li, K	1
Gao, C	1
Wang, X	1
Vanderburg, D	1
Pan, S	1
Tang, H	1
Shu, L	1
Karayal, ON	1
Fongemie, JM	1
Al-Qadheeb, NS	2
Estes, NA	1
Roberts, RJ	2
Temtanakitpaisan, Y	1
Ruthazer, R	1
Devlin, JW	2
Gillies, D	1
Sampson, S	1
Beck, A	1
Rathbone, J	2
Zirker, W	1
Dorokhine, I	1
Knapp, CM	1
Patel, N	1
Musuku, M	1
Atalan, N	1
Efe Sevim, M	1
Akgün, S	1
Fazlıoğulları, O	1
Başaran, C	1
Wachtel, LE	1
Reti, IM	1
Ying, H	1
Bascom, PB	1
Bordley, JL	1
Lawton, AJ	1
Chandler, A	1
Freeze-Ramsey, R	1
Seupaul, RA	1
Walther, S	1
Moggi, F	1
Horn, H	1
Moskvitin, K	1
Abderhalden, C	1
Maier, N	1
Strik, W	1
Müller, TJ	1
Suzuki, H	1
Gen, K	1
Takahashi, Y	1
Gambles, M	1
McGlinchey, T	1
Latten, R	1
Dickman, A	2
Lowe, D	1
Ellershaw, JE	1
Szegő, A	1
Eleméry, M	1
Faludi, G	1
Kovács, G	1
Chan, HY	1
Ree, SC	1
Su, LW	1
Chen, JJ	1
Chou, SY	1
Chen, CK	1
Chen, YS	1
Gao, J	1
Li, M	1
Hagino, Y	1
Kasai, S	1
Fujita, M	1
Setogawa, S	1
Yamaura, H	1
Yanagihara, D	1
Hashimoto, M	1
Kobayashi, K	1
Meltzer, HY	1
Calver, L	1
Drinkwater, V	1
Gupta, R	1
Page, CB	1
Isbister, GK	1
Asadollahi, S	1
Heidari, K	1
Hatamabadi, H	1
Vafaee, R	1
Yunesian, S	1
Azadbakht, A	1
Mirmohseni, L	1
Huang, CL	1
Hwang, TJ	1
Chen, YH	1
Huang, GH	1
Hsieh, MH	1
Chen, HH	1
Hwu, HG	1
Hayes, A	1
Russ, MJ	1
Kishi, T	1
Matsunaga, S	1
Iwata, N	1
Gonçalves, F	2
Almeida, A	3
Pereira, S	2
Isenberg, DL	1
Jacobs, D	1
Skrobik, Y	1
Schumaker, G	1
Pacheco, MN	1
Ruthazer, RR	1
Gortney, JS	1
Raub, JN	1
Patel, P	1
Kokoska, L	1
Hannawa, M	1
Argyris, A	1
Carrasco, G	1
Baeza, N	1
Cabré, L	1
Portillo, E	1
Gimeno, G	1
Manzanedo, D	1
Calizaya, M	1
McCullough, LB	1
Chervenak, FA	1
Coverdale, JH	1
Kenes, MT	1
Hamblin, SE	1
Tumuluri, SS	1
Guillamondegui, OD	1
Moore, JC	1
Nystrom, PC	1
Orozco, BS	1
Stellpflug, SJ	1
Kornas, RL	1
Fryza, BJ	1
Steinberg, LW	1
O'Brien-Lambert, A	1
Bache-Wiig, P	1
Engebretsen, KM	1
Ho, JD	1
Bauer, JØ	1
Stenborg, D	1
Lodahl, T	1
Mønsted, MM	1
Cameron, R	1
Ferraz Gonçalves, JA	1
Costa, I	1
Silva, P	1
Carneiro, R	1
Gomez, S	1
Dopheide, J	1
Huf, G	7
Alexander, J	5
Gandhi, P	1
Allen, MH	4
Khokhar, MA	1
Sirois, F	1
Hoffman, AN	1
Cheng, JP	1
Zafonte, RD	1
Massucci, JL	1
Künzel, HE	1
Ackl, N	1
Hatzinger, M	1
Held, K	1
Holsboer-Trachsler, E	1
Ising, M	1
Kaschka, W	1
Kasper, S	1
Konstantinidis, A	1
Sonntag, A	1
Uhr, M	1
Yassouridis, A	1
Holsboer, F	1
Steiger, A	1
San, L	2
Castle, DJ	1
Udristoiu, T	1
Kim, CY	1
Sarosi, A	1
Pidrman, V	1
Omar, AN	1
Rosales, JI	1
Melamed, Y	1
Isik, T	1
Karagianis, J	1
Treuer, T	1
Bellamy, CJ	1
Kane-Gill, SL	1
Falcione, BA	1
Seybert, AL	1
Weinberg, G	1
Di Gregorio, G	1
Hiller, D	1
Hewett, A	1
Sirianni, A	1
Reade, MC	1
O'Sullivan, K	1
Bates, S	1
Goldsmith, D	1
Ainslie, WR	1
Bellomo, R	1
Raveendran, NS	2
Page, VJ	1
Freeman, DJ	1
DiPaula, BA	1
Love, RC	1
Coutinho, ES	3
Kane, JM	1
Barnes, TR	1
Correll, CU	1
Sachs, G	1
Buckley, P	1
Eudicone, J	2
McQuade, R	3
Tran, QV	1
Pikalov, A	1
Assunção-Talbott, S	1
Birmingham, C	1
Ban, K	1
Rosen, P	1
Wolfe, R	1
Davis, D	1
Sakles, J	1
Bramwell, K	1
Sanchez, LD	1
Leung, JG	1
Benedetti, AM	1
Frazee, LA	1
Myers, N	1
Ahmed, U	1
Jones, H	2
Desai, A	1
Nierenberg, DW	1
Duhaime, AC	1
Hsu, WY	1
Huang, SS	1
Lee, BS	1
Chiu, NY	1
Lim, HK	1
Kim, JJ	1
Pae, CU	1
Lee, CU	1
Lee, C	1
Paik, IH	1
Docherty, JP	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Open-label Randomized Controlled Trial of Oral Transmucosal Haloperidol and Olanzapine in the Treatment of Terminal Delirium[NCT04750395]	Phase 2	80 participants (Anticipated)	Interventional	2021-09-01	Recruiting
Haloperidol and/or Chlorpromazine for Refractory Agitated Delirium in the Palliative Care Unit[NCT03021486]	Phase 2/Phase 3	70 participants (Actual)	Interventional	2017-06-05	Active, not recruiting
Mindful Melody: Feasibility of Implementing Music Listening on an Inpatient Psychiatric Unit and Its Relation to the Use of As Needed Medications for Acute Agitation[NCT04514432]		172 participants (Actual)	Observational	2018-08-16	Completed
Prospective Observational Investigation of Olanzapine Versus Haloperidol Versus Ziprasidone Versus Midazolam for the Treatment of Acute Undifferentiated Agitation in the Emergency Department[NCT03211897]		737 participants (Actual)	Observational	2017-06-15	Completed
Rapid Agitation Control With Ketamine in the Emergency Department (RACKED): a Randomized Controlled Trial[NCT03375671]	Phase 2	81 participants (Actual)	Interventional	2018-05-29	Completed
An Observational Study of Anti-Psychotic Medication for the Treatment of Agitation in the Emergency Department[NCT02877108]		100 participants (Anticipated)	Observational	2016-04-30	Recruiting
A Multi-Center,Open-Labeled,Intervention Study:The Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic Agitation[NCT02935998]	Phase 4	1,000 participants (Anticipated)	Interventional	2016-10-31	Not yet recruiting
A Randomized, Open Label, Rater Blind, Flexible Dose Multi-Center Study Comparing The Efficacy And Safety Of Intramuscular Ziprasidone With Haloperidol For Three Days In Patients With Agitation Of Schizophrenia[NCT00723606]	Phase 3	376 participants (Actual)	Interventional	2008-09-30	Completed
An Open-label, Randomized Trial of Intramuscular (IM) Olanzapine Versus Intramuscular Combination of Haloperidol and Lorazepam in the Treatment of Acute Agitation in Schizophrenia[NCT00797277]	Phase 3	67 participants (Actual)	Interventional	2006-07-31	Completed
Ketamine Versus Midazolam for Prehospital Agitation[NCT03554915]		314 participants (Actual)	Observational	2017-08-01	Completed
Effect of Clonidine vs. Dexmedetomidine in Addition to Standard Treatment in Agitated Delirium in Intensive Care Patients: Pilot Study.[NCT04758936]	Phase 4	50 participants (Anticipated)	Interventional	2021-02-01	Recruiting
A Randomised Open Label Pilot Study of the Efficacy of Dexmedetomidine and Haloperidol in Ventilated Patients With ICU-associated Agitation and Delirium[NCT00505804]	Phase 2	20 participants (Actual)	Interventional	2005-01-31	Completed
Treatment of Behavioral Symptoms in Alzheimer's Disease[NCT00009217]	Phase 4	44 participants (Actual)	Interventional	1999-01-31	Completed
Maintenance Treatment vs. Stepwise Drug Discontinuation After One Year of Maintenance Treatment in First-Episode Schizophrenia[NCT00159120]	Phase 4	71 participants (Anticipated)	Interventional	2001-11-30	Completed
Rapid Tranquilization of Violent or Agitated People in Psychiatric Emergency Settings- A Pragmatic Randomized Controlled Trial of Intramuscular Olanzepine Vs. Intramuscular Haloperidol + Promethazine.[NCT00455234]	Phase 3	300 participants	Interventional	2005-09-30	Completed
A Randomized Prospective Pilot Study Of Haloperidol In Addition To Standard Sedation In Mechanically Ventilated Patients With Delirium[NCT00429676]	Phase 2	20 participants (Anticipated)	Interventional	2005-12-31	Completed
ORIC-I: Optimizing Recovery From Intensive Care: Mechanical Ventilation and Delirium[NCT00300391]	Phase 3	40 participants (Actual)	Interventional	2006-03-31	Terminated (stopped due to Insufficient recruitment to meet aims.)
Randomized Double-Blind Clinical Trial to Compare Haloperidol and Non-Pharmacologic Treatment Versus Non-Pharmacologic Treatment and Placebo, in Elderly Hospitalized Patients With Hypoactive Delirium[NCT02345902]	Phase 3	60 participants (Anticipated)	Interventional	2016-01-31	Recruiting
Treatment of Psychosis and Agitation in Alzheimer's Disease[NCT02129348]	Phase 2	77 participants (Actual)	Interventional	2014-06-30	Completed
[NCT00000179]	Phase 3	0 participants	Interventional		Completed
Elderly Patients With Dementia in the Department of Acute Geriatrics: Pilot Study, Monocentric, Randomized Use of Aromatherapy as a Complementary Treatment to Psychopharmacotherapy in Psychological Disorders and BPSD Behavior[NCT03662360]		32 participants (Actual)	Interventional	2018-05-20	Completed
Can Virtual Reality Reduce Depression and Agitation in Older Adults With Moderate to Severe Dementia? A Randomized Controlled Trial.[NCT04347668]		266 participants (Anticipated)	Interventional	2019-04-01	Recruiting
Low Dose Ionizing Radiation Using CT Scans as a Potential Therapy for Alzheimer's Dementia (LDIR-CT-AD) Trial: A Pilot Study[NCT03597360]		4 participants (Actual)	Interventional	2019-01-08	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

RASS score is a 10-point scale with scores ranging from +4 (very combative, violent) to -5 (unarousable). The secondary outcome was mean change in RASS score between time 0 (immediately before initiation of masked treatment) and 30 minutes later. The Richmond Agitation-Sedation Scale (RASS) was developed by a multidisciplinary team at Virginia Commonwealth University in Richmond; it is a validated method used to avoid over sedation in the Intensive Care Unit. (NCT03021486)
Timeframe: Time 0 or Baseline and 30 minutes later.

Change in Richmond Agitation Sedation Score (RASS) (0-24h)

Intervention	score on a scale (Mean)
Escalation Group	-2.6
Rotation Group	-2.4
Combination Group	-2.1

RASS score is a 10-point scale with scores ranging from +4 (very combative, violent) to -5 (unarousable). The primary outcome was mean change in RASS score between time 0 (immediately before initiation of masked treatment) and 24 h later. The Richmond Agitation-Sedation Scale (RASS) was developed by a multidisciplinary team at Virginia Commonwealth University in Richmond; it is a validated method used to avoid oversedation in the Intensive Care Unit. (NCT03021486)
Timeframe: Time 0 or Baseline and 24 hours after study medication administration

Memorial Delirium Assessment Scale (MDAS)

Intervention	score on a scale (Mean)
Escalation Group	-3.6
Rotation Group	-3.3
Combination Group	-3.0

The Memorial Delirium Assessment Scale (MDAS) is a 10-item clinician-rated assessment scale validated for assessment of delirium in cancer patients. It examines the level of consciousness, disorientation, memory, recall, attention, disorganized thinking, perceptual disturbance, delusions, psychomotor activity and sleep, assigning a score between 0 to 3, for a total score between 0-30. A total score of 13 or higher indicates delirium. We measured the change in Memorial Delirium Rating scale between baseline and 24 hours. (NCT03021486)
Timeframe: Baseline and 24 hours

Number of Participants With RASS Score of >=1

Intervention	score on a scale (Mean)
Escalation Group	-2.7
Rotation Group	1
Combination Group	0.3

RASS score is a 10-point scale with scores ranging from +4 (very combative, violent) to -5 (unarousable). The secondary outcome was the proportion of breakthrough restlessness participants with a RASS score of >=1 during the first 24 hours. The Richmond Agitation-Sedation Scale (RASS) was developed by a multidisciplinary team at Virginia Commonwealth University in Richmond; it is a validated method used to avoid oversedation in the Intensive Care Unit. (NCT03021486)
Timeframe: 0 or Baseline and 24 hours later

Percentage of Participants With RASS Score -2 to 0

Intervention	Participants (Count of Participants)
Escalation Group	12
Rotation Group	7
Combination Group	9

RASS score is a 10-point scale with scores ranging from +4 (very combative, violent) to -5 (unarousable). The Secondary outcome was the percentage of participants with target RASS score of -2 to 0 within the first 24 hours. The Richmond Agitation-Sedation Scale (RASS) was developed by a multidisciplinary team at Virginia Commonwealth University in Richmond; it is a validated method used to avoid over sedation in the Intensive Care Unit. (NCT03021486)
Timeframe: Time 0 or Baseline and 24 hours later.

Change in Delirium Experience Questionnaire

Intervention	Participants (Count of Participants)
Escalation Group	2
Rotation Group	3
Combination Group	5

This 14-item questionnaire examines both the recalled frequency of 7 delirium symptoms and associated distress in the rater: disorientation to time, disorientation to place, visual hallucinations, tactile hallucinations, auditory hallucinations, delusional thoughts and psychomotor agitation. The score for recalled frequency ranges between 0 and 4, where 0=not present, 1=a little of the time, 2=some of the time, 3=good part of the time, and 4=most or all of the time. The score for distress in the rater related to each delirium symptom also ranges from 0 to 4, where 0=no distress, 1=a little, 2=a fair amount, 3=very much and 4=extremely distressed. Due to an error in the data collection form, the last category was omitted as a choice and thus the score only ranged from 0 to 3. (NCT03021486)
Timeframe: Baseline and Day 3

Edmonton Expression Assessment System, ESAS

Intervention	score on a scale (Mean)
	Nursing assessment, disorientation to time - frequency	Nursing assessment, disorientation to place - frequency	Nursing assessment, visual hallucination - frequency	Nursing assessment, tactile hallucination - frequency	Nursing assessment, auditory hallucination - frequency	Nursing assessment, delusional thoughts - frequency	Nursing assessment, psychomotor agitation- frequency	Nursing assessment, disorientation to time - distress	Nursing assessment, disorientation to place - distress	Nursing assessment, visual hallucination - distress	Nursing assessment, tactile hallucination - distress	Nursing assessment, auditory hallucination - distress	Nursing assessment, delusional thoughts - distress	Nursing assessment, psychomotor agitation - distress
Combination Group	0.2	0.3	-0.7	-0.9	-0.4	0.2	-0.4	-0.5	-0.4	-0.4	-0.5	-0.2	-0.1	-0.8
Escalation Group	-0.8	-0.9	-1	-0.4	-0.1	-0.8	-1.2	-0.3	-0.3	-0.6	-0.5	-0.3	-0.6	-0.8
Rotation Group	-0.8	-0.8	0	0.1	0.1	0	-0.8	-0.3	-0.3	0.1	0	0	0	-0.5

Edmonton Symptom Assessment System (ESAS) has been validated and widely used in different clinical settings, including the acute palliative care unit. It assessed the average symptom intensity of 10 symptoms over the past 24 hours. Each symptom was assessed using an 11-point numeric rating scale, ranging from 0 (none) to 10 (worst). It was measured as change in ESAS as Perceived by Caregivers between baseline and day 1, mean. (NCT03021486)
Timeframe: Baseline and 24 hours

Pattern of Medication Use

Intervention	score on a scale (Mean)
	Pain	Fatigue	Nausea	Depression	Anxiety	Drowsiness	Appetite	Feeling of well being*	Shortness of breath	Sleep
Combination Group	-1.1	1	-0.4	-0.8	-0.9	0.7	0.1	0	0	-2.7
Escalation Group	-1.3	-0.5	0.1	-1.4	-1.5	-0.2	-0.3	0.2	0.8	-2.7
Rotation Group	-4.1	-3	-1.8	-1.2	-4.8	-0.6	-0.6	-1.6	-2.2	-5.1

Use of neuroleptics and benzodiazepines during the first 24 hours was retrieved from the Medication Administration Record. (NCT03021486)
Timeframe: Baseline and 24 hours

Perceived Comfort Level as Assessed by Caregiver

Intervention	Participants (Count of Participants)
	Need for study med dose escalation in first 24 hrs	Benzodiazepine use in first 24 hrs (scheduled)	Benzodiazepine use in first 24 hrs (as needed)
Combination Group	7	0	4
Escalation Group	4	1	0
Rotation Group	1	0	0

"On day 1 (after initiation of blinded treatment), we asked the blinded caregivers to provide their overall impression of change in patient comfort level and the agitation level. The response ranged from strongly agree, agree, neutral, disagree, and strongly disagree. In this study, strongly agree and agree were combined for analysis. The participants who reported 'Agree' and 'Strongly Agree' responses to perceived comfort level have a high level of comfort (more comfortable). And similarly, the participants who reported 'Agree' and 'Strongly Agree' responses to perceived agitation level have a low level of agitation (less agitated)." (NCT03021486)
Timeframe: Baseline and 24 hour

Perceived Comfort Level as Assessed by Nurse

Intervention	Participants (Count of Participants)
	Perceived To Have A High Level of Comfort (More Comfortable)	Perceived To Have A Low Level of Agitation (Less Agitated)
Combination Group	6	6
Escalation Group	8	9
Rotation Group	10	10

Udvalg for Kliniske Undersogelser, UKU

Intervention	Participants (Count of Participants)
	Perceived To Have A High Level of Comfort (More Comfortable)	Perceived To Have A Low Level of Agitation (Less Agitated)
Combination Group	7	7
Escalation Group	9	8
Rotation Group	9	8

We also documented the selected adverse effects associated with neuroleptics using the Udvalg for Kliniske Undersogelser (UKU) side effects rating scale. Specifically, we assessed 8 neurologic symptoms (dystonia, rigidity, hypokinesia/akinesia, hyperkinesia, tremor, akathisia, epileptic seizures, paraesthesias). We are reporting only the neurologic symptoms (tremor and akathisia) that had changes during the study. Each item was assigned a score by the research coordinator 0 (absent) to 3 (most severe) based on symptom severity of the last 3 days. (NCT03021486)
Timeframe: Baseline and 3 days

Change From Baseline in Behavioral Activity Rating Scale (BARS) at 72 Hours

Intervention	Participants (Count of Participants)
	Tremor (decreased)	Akathisia (decreased)
Combination Group	1	1
Escalation Group	0	0
Rotation Group	0	0

BARS measures the degree of agitated behavior using a 7-point scale describing increasing levels of activity (1 =difficult or unable to rouse; 2 = asleep but responds normally to verbal or physical contact; 3 = drowsy, appears sedated; 4 = quiet and awake [normal level of activity]; 5 = signs of overt [physical or verbal] activity, calms down with instructions; 6 = extremely or continuously active, not requiring restraint; 7 = violent, requires restraint. (NCT00723606)
Timeframe: Baseline, 72 hours

Change From Baseline in BPRS Agitation Subscale Score at 72 Hours

Intervention	scores on a scale (Least Squares Mean)
Ziprasidone	-0.93
Haloperidol	-1.06

The BPRS agitation subscale score was composed of 4 questions (questions 2, 6, 10, 17). The BPRS agitation subscale score was obtained by summing the relevant individual items. Total possible score range=4 to 28. Change: score at final visit minus score at baseline. (NCT00723606)
Timeframe: Baseline, 72 hours

Change From Baseline in Brief Psychiatric Rating Scale (BPRS) Total Scores at 72 Hours

Intervention	scores on a scale (Least Squares Mean)
Ziprasidone	-6.97
Haloperidol	-7.45

BPRS is an 18-item clinician rated scale with 11 general symptom items, 5 positive-symptom items, and 2 negative symptom items scored on a 7-point scale (1=not present and 7=extremely severe), with higher score indicating greater severity of symptom. Total possible score range=18 to 126. Change: score at final visit minus score at baseline. (NCT00723606)
Timeframe: Baseline, 72 hours

Change From Baseline in Clinical Global Impressions Severity (CGI-S) Score at 72 Hours

Intervention	scores on a scale (Least Squares Mean)
Ziprasidone	-17.32
Haloperidol	-18.44

CGI-S: 7-point clinician rated scale to assess severity of subject's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected. Change: score at observation minus score at baseline. (NCT00723606)
Timeframe: Baseline, 72 hours

Clinical Global Impression-Improvement (CGI-I) Score at 72 Hours

Intervention	scores on a scale (Least Squares Mean)
Ziprasidone	-1.18
Haloperidol	-1.21

CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected. (NCT00723606)
Timeframe: 72 hours

BPRS Agitation Subscale Response at 72 Hours

Intervention	scores on a scale (Least Squares Mean)
Ziprasidone	2.52
Haloperidol	2.55

The BPRS agitation subscale score was composed of 4 questions (questions 2, 6, 10, 17). The BPRS agitation subscale score was obtained by summing the relevant individual items. Total possible score range=4 to 28. A response was defined as a > 30 percent reduction from baseline in BPRS agitation subscale score. (NCT00723606)
Timeframe: 72 hours

Change of the Agitation-Calmness Evaluation Scale (ACES) Score From Baseline to 120 Minutes After 1st Injection

Intervention	participants (Number)
	Response	No Response
Haloperidol	155	29
Ziprasidone	149	39

Agitation was further assessed by the Agitation Calmness Evaluation Scale (ACES) (Copyright 1998, Eli Lilly and Company), a single-item scale developed by Eli Lilly and Company on which 1 indicates marked agitation; 2, moderate agitation; 3, mild agitation; 4, normal; 5, mild calmness; 6, moderate calmness; 7, marked calmness; 8, deep sleep; and 9, unable to be aroused. (NCT00797277)
Timeframe: from baseline to 120 minutes after first injection

The Change of the Positive and Negative Symptom Scale Excited Component (PANSS-EC) Score From Baseline to 120 Minutes After First Injection

Intervention	units on a scale (Mean)
1. IM Olanzapine	2.14
2. IM Haloperidol Pus Lorazepam	2.23

The primary efficacy measure was PANSS-EC, which was derived from the PANSS by its originators using a principal-components factor analysis, and includes the items of tension, uncooperativeness, hostility, poor impulse control and excitement.22 The score of each item ranges from 1 (normal) to 7 (most severe), with a total sum score ranging from 5 to 35. The changes in PANSS-EC from baseline to 2 hours after the first injection were compared. (NCT00797277)
Timeframe: from baseline to 120 minutes after first injection

28-day All-cause Mortality

90-day All-cause Mortality

Duration of Mechanical Ventilation

ICU Length of Stay

Basic Activities of Daily Living (BADL)

Intervention	units on a scale (Mean)
1. IM Olanzapine	-10.2
2. IM Haloperidol Plus Lorazepam	-9.9

Intervention	Participants (Count of Participants)
Delirium	4
Persistent Coma	2
No Delirium	1

Intervention	Participants (Count of Participants)
Delirium	4
Persistent Coma	2
No Delirium	1

Intervention	day (Median)
Delirium	4.5
Persistent Coma	6
No Delirium	4

Intervention	day (Median)
Delirium	9
Persistent Coma	6
No Delirium	7

Basic Activities of Daily Living with items for 6 functions: bathing, dressing, toileting, transferring, continence, and feeding. Each item is scored as unimpaired=1, impaired=0. Total score is the measure used, range 0-6; higher scores indicate better functioning. (NCT02129348)
Timeframe: Assessed at Week 0, Week2, Week 4, Week 6, Week 8, Week 10, Week 12

Change in Neuropsychiatric Inventory (NPI) Agitation/Aggression Domain Score

Intervention	score on a scale (Least Squares Mean)
Lithium Treatment Group	0.3
Placebo Group	0.1

Neuropsychiatric Inventory (NPI) Agitation/Aggression Domain is the measure used that combines symptoms of agitation and aggression. Frequency X Severity rating score, range 0-12. Higher score indicates more agitation and aggressive behavior. (NCT02129348)
Timeframe: Assessed at screening, Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12

Clinical Global Impression (CGI) Behavior Change

Intervention	score on a scale (Least Squares Mean)
Lithium Treatment Group	3.2
Placebo Group	2.5

Clinical Global Impression (CGI) Behavior Change score is the measure used to assess change in overall behavior; scoring range 1-7 with higher scores indicating worsening over time and lower scores indicating improvement over time. Scores ranging from 1-3 indicate improvement. Only patients that demonstrated improvement at week 12 were reported; scores for earlier weeks were only used to assess progress throughout the study. (NCT02129348)
Timeframe: Week 12

Clinical Responder Defined as a 30% Decrease in NPI Core Score (Sum Score of NPI Domains of Agitation/Aggression, Delusions and Hallucinations) Together With a Clinical Global Impression (CGI) Behavior Change Score of 1 or 2

Intervention	Participants (Count of Participants)
Lithium Treatment Group	12
Placebo Group	8

The patient is classified as a responder (score=1) if both criteria are met or as a non-responder (score=0) if both criteria are not met. The first criterion to determine responder status, NPI core score, has a scoring range 0-36; each of the three component scores for symptoms of agitation/aggression, delusions and hallucinations has a scoring range 0-12. For each symptom and the total score, higher score indicates more symptoms. The second criterion to determine responder status, Clinical Global Impression (CGI), is used to assess change in overall behavior; scoring range 1-7 with higher scores indicating worsening over time and lower scores indicating improvement over time. Only patients who met both criteria, assessed as change compared to baseline, were counted as responders; all other patients were non-responders. Patients that demonstrated improvement at week 12 were reported; scores for earlier weeks were only used to assess progress throughout the study. (NCT02129348)
Timeframe: Week 12

Folstein Mini-Mental Status Exam

Intervention	Participants (Count of Participants)
Lithium Treatment Group	12
Placebo Group	7

30 item questionnaire used to assess degree of cognitive impairment. Orientation, registration, attention/calculation, recall, language, repetitions and commands are assessed. Total score is the measure used; range 0-30, higher scores indicate better global cognitive function. (NCT02129348)
Timeframe: Assessed at Screening, Week 12

Severe Impairment Battery

Intervention	score on a scale (Least Squares Mean)
Lithium Treatment Group	0.9
Placebo Group	0.9

Neuropsychological test used to assess a patient's cognitive ability. The patient is asked to complete small tasks such as drawing shapes and printing their name. They are also asked to remember certain names and objects, such as a cup and a spoon, and the evaluator's first name. Total score is the measure used; range 0-100, higher scores indicate better cognition. (NCT02129348)
Timeframe: Assessed at Week 0, Week 12

Simpson-Angus Scale

Intervention	score on a scale (Least Squares Mean)
Lithium Treatment Group	2.1
Placebo Group	-0.0

Simpson Angus Scale for Extrapyramidal Sign requires in-person examination to assess gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, leg pendulousness, head dropping, glabella tap, tremor, and salivation. Total score is the measure used, range 0-40; higher scores indicate increased severity of signs. (NCT02129348)
Timeframe: Assessed at Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12

Treatment Emergent Signs and Symptoms

Intervention	score on a scale (Least Squares Mean)
Lithium Treatment Group	-0.0
Placebo Group	0.0

Treatment Emergent Symptom Scale that covers 26 somatic symptoms, each rated as present (score=1) or absent (score=0). Total score is the measure used with scoring range 0-26; higher scores indicate more somatic symptoms. (NCT02129348)
Timeframe: Assessed at Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12

Young Mania Rating Scale

Intervention	score on a scale (Least Squares Mean)
Lithium Treatment Group	0.6
Placebo Group	0.7

Young Mania Rating Scale total score is the measure used to assess symptoms that occur in mania; each item is a symptom that is rated for severity. Scoring range 0-60; higher scores indicate more severe symptoms. (NCT02129348)
Timeframe: Assessed at Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12

Zarit Caregiver Burden Interview

Intervention	score on a scale (Least Squares Mean)
Lithium Treatment Group	3.1
Placebo Group	1.1

Zarit Caregiver Burden Interview with the caregiver asked to rank 22 items on a scale with responses for each item from 'never' (score 0) to 'nearly always' (score 4). Total score is the measure used; range 0-88 with higher scores indicating greater caregiver burden. (NCT02129348)
Timeframe: Assessed at Week 0, Week 4, Week 8, Week 10, Week 12

Role of Essential Oil Therapy in Environmental Diffusion as a Complement of Psychotropic Drugs in the Management of Psychological and Behavioral Disorders (BPSD)

Intervention	score on a scale (Least Squares Mean)
Lithium Treatment Group	2.8
Placebo Group	-0.4

"The Neuropsychiatric Inventory - Nursing Home Version (NPI-NH) test will characterize the neuropsychiatric and psychopathological symptoms of patients affected by dementia.~Events as delirium, anxiety, depression, etc. will be recorded by the frequency (from 0, absence, to 4, high frequency) and the seriousness (from 0, absence, to 3, high). The total score of the NPI-NH is given by the frequency x (multiply) seriousness (total score for each event has a range from 0 to 12). The patient final score will be given by the sum of the score of the 12 events. For each patient will be given a total score from 0 to 144.~NPI NH score has been collected in both control and aromatherapy groups at T1 and T3, in patients who needed and who did not needed Pro Re Nata." (NCT03662360)
Timeframe: Time 1 (baseline) and Time 3 (day 7)

Role of Essential Oil Therapy in Environmental Diffusion in Professional Caregiver Distress Linked to BPSD

Intervention	score on a scale (Mean)
	T1 NPI score in patients do not need Pro Re Nata	T3 NPI score in patients needed Pro Re Nata	T3 NPI score in patients do not need Pro Re Nata
GROUP A - Control Group	21.81	32.87	20.00
GROUP B - Aromatherapy Group	25.93	16.5	7.25

NPI-NH assess the psychological distress in physicians, nurses and nursing assistants who managed the patients. It has a score from 0 (no discomfort) to score of 5 (extreme discomfort). The psychological distress is measured for each of the 12 events in the NPI-NH scale, for a total score from 0 to 60. (NCT03662360)
Timeframe: Time 1 (baseline) and Time 3 (day 7)

Intervention	score on a scale (Mean)
	T1 NPI NH physicians in pts with PRN	T1 NPI NH physicians in pts without PRN	T1 NPI NH nurses in pts with PRN	T1 NPI NH nurses in pts without PRN	T1 NPI NH nursing assistants in pts with PRN	T1 NPI NH nursing assistants in pts without PRN	T3 NPI NH physician in pts with PRN	T3 NPI NH physician in pts without PRN	T3 NPI NH nurses in pts with PRN	T3 NPI NH nurses in pts without PRN	T3 NPI NH nursing assistants in pts with PRN	T3 NPI NH nursing assistants in pts without PRN
GROUP A - Control Group	4.19	1.60	9.63	6.40	11.00	7.10	6.00	3.20	12.00	9.30	13.19	9.90
GROUP B - Aromatherapy Group	5.64	4.13	11.64	10.13	12.21	10.88	2.64	0.88	5.79	4.25	5.93	4.38

Article	Year
Haloperidol Versus Ziprasidone With Concomitant Medications and Other Predictors of Physical Restraint Duration in the Emergency Department. The Journal of emergency medicine, 2022, Volume: 62, Issue:5 Topics: Antipsychotic Agents; Emergency Service, Hospital; Haloperidol; Humans; Piperazines; Psychomotor Agi	2022
Psychopharmacology of agitation in acute psychotic and manic episodes. Current opinion in psychiatry, 2022, 05-01, Volume: 35, Issue:3 Topics: Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Haloperidol; Humans; Lorazepam; Ma	2022
The Use of Rapid Tranquilization in Aggressive Behavior. Deutsches Arzteblatt international, 2019, Jun-28, Volume: 116, Issue:26 Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Psychomotor Agitation; Psych	2019
Short-acting intramuscular second-generation antipsychotic drugs for acutely agitated patients with schizophrenia spectrum disorders. A systematic review and network meta-analysis. Schizophrenia research, 2021, Volume: 229 Topics: Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Injections, Intramuscular; Network Meta-	2021
Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation). The Cochrane database of systematic reviews, 2017, 07-31, Volume: 7 Topics: Aggression; Antipsychotic Agents; Dystonia; Haloperidol; Humans; Hypnotics and Sedatives; Placebos;	2017
Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation). The Cochrane database of systematic reviews, 2018, 01-08, Volume: 1 Topics: Aggression; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Haloperidol; Humans; Injections, In	2018
Evidence-Based Review of Pharmacotherapy for Acute Agitation. Part 1: Onset of Efficacy. The Journal of emergency medicine, 2018, Volume: 54, Issue:3 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Drug Therapy; Evidence-Based Practice; Haloperi	2018
Evidence-Based Review Of Pharmacotherapy For Acute Agitation. Part 2: Safety. The Journal of emergency medicine, 2018, Volume: 54, Issue:4 Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Emergency Service, Hospital; Evidence	2018
The pharmacological management of agitated and aggressive behaviour: A systematic review and meta-analysis. European psychiatry : the journal of the Association of European Psychiatrists, 2019, Volume: 57 Topics: Aggression; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; H	2019
Benzodiazepines for psychosis-induced aggression or agitation. The Cochrane database of systematic reviews, 2013, Apr-30, Issue:4 Topics: Acute Disease; Aggression; Anti-Dyskinesia Agents; Antipsychotic Agents; Benzodiazepines; Drug Thera	2013
Intramuscular olanzapine for agitated patients: A systematic review and meta-analysis of randomized controlled trials. Journal of psychiatric research, 2015, Volume: 68 Topics: Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Olanzapine; Psychomotor Agitation; Rando	2015
Alcohol withdrawal syndrome in medical patients. Cleveland Clinic journal of medicine, 2016, Volume: 83, Issue:1 Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic beta-Antagonists; Alcohol Withdrawal Delirium; Alco	2016
Haloperidol plus promethazine for psychosis-induced aggression. The Cochrane database of systematic reviews, 2016, 11-25, Volume: 11 Topics: Aggression; Benzodiazepines; Drug Therapy, Combination; Haloperidol; Humans; Lorazepam; Midazolam; P	2016
Droperidol for psychosis-induced aggression or agitation. The Cochrane database of systematic reviews, 2016, 12-15, Volume: 12 Topics: Acute Disease; Aggression; Antipsychotic Agents; Benzodiazepines; Droperidol; Haloperidol; Humans; M	2016
[Clinical and therapeutic aspects of agitation]. L'Encephale, 2007, Volume: 33 Pt 3 Topics: Acute Disease; Aggression; Antipsychotic Agents; Benzodiazepines; Controlled Clinical Trials as Topi	2007
Neuroleptic malignant syndrome in traumatic brain injury patients treated with haloperidol. The Journal of trauma, 2009, Volume: 66, Issue:3 Topics: Adolescent; Adult; Antipsychotic Agents; Brain Injuries; Cerebral Hemorrhage, Traumatic; Combined Mo	2009
Haloperidol plus promethazine for psychosis-induced aggression. The Cochrane database of systematic reviews, 2009, Jul-08, Issue:3 Topics: Aggression; Benzodiazepines; Drug Therapy, Combination; Haloperidol; Humans; Lorazepam; Midazolam; O	2009
[Haloperidol plus promethazine for agitated patients--a systematic review]. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), 2009, Volume: 31, Issue:3 Topics: Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Haloperidol;	2009
Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials. Journal of psychopharmacology (Oxford, England), 2010, Volume: 24, Issue:7 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Double-Blind Method; Haloperi	2010
Chlorpromazine for psychosis induced aggression or agitation. The Cochrane database of systematic reviews, 2010, Apr-14, Issue:4 Topics: Administration, Oral; Aggression; Antipsychotic Agents; Chlorpromazine; Haloperidol; Humans; Injecti	2010
Confusion, agitation and delirium. Frontiers of neurology and neuroscience, 2012, Volume: 30 Topics: Antipsychotic Agents; Confusion; Delirium; Haloperidol; Humans; Prevalence; Psychomotor Agitation; R	2012
Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation). The Cochrane database of systematic reviews, 2012, Nov-14, Volume: 11 Topics: Aggression; Antipsychotic Agents; Aripiprazole; Clopenthixol; Dystonia; Haloperidol; Humans; Lorazep	2012
Recent developments in pharmacotherapy for the acutely psychotic patient. Journal of emergency nursing, 2002, Volume: 28, Issue:6 Suppl Topics: Anti-Dyskinesia Agents; Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Injections, Intr	2002
Distinguishing PANDAS from Sydenham's chorea: case report and review of the literature. European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society, 2004, Volume: 8, Issue:4 Topics: Child; Chorea; Diagnosis, Differential; Haloperidol; Humans; Long-Term Care; Male; Neurologic Examin	2004
Haloperidol plus promethazine for psychosis induced aggression. The Cochrane database of systematic reviews, 2005, Jan-25, Issue:1 Topics: Aggression; Drug Therapy, Combination; Haloperidol; Humans; Lorazepam; Midazolam; Promethazine; Psyc	2005
The evaluation and management of the acutely agitated elderly patient. The Mount Sinai journal of medicine, New York, 2006, Volume: 73, Issue:7 Topics: Aged; Antipsychotic Agents; Benzodiazepines; Dementia; Diagnosis, Differential; Drug Therapy, Combin	2006
Neuroleptic malignant syndrome in a trauma patient. The Journal of trauma, 1995, Volume: 39, Issue:4 Topics: Adult; Antipsychotic Agents; Dantrolene; Droperidol; Haloperidol; Humans; Male; Multiple Trauma; Mus	1995
Pharmacological interventions for agitation in head-injured patients in the acute care setting. The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses, 1995, Volume: 27, Issue:2 Topics: Adult; Brain Injuries; Critical Care; Dose-Response Relationship, Drug; Drug Administration Schedule	1995
The agitated patient, Part II: Pharmacologic treatment. Hospital & community psychiatry, 1993, Volume: 44, Issue:7 Topics: Akathisia, Drug-Induced; Drug Therapy, Combination; Emergencies; Haloperidol; Humans; Lorazepam; Neu	1993
[Neuroleptic malignant syndrome]. Revue medicale de la Suisse romande, 1996, Volume: 116, Issue:9 Topics: Adolescent; Adult; Antipsychotic Agents; Diagnosis, Differential; Dibenzothiazepines; Female; Halope	1996
Droperidol: efficacy and side effects in psychiatric emergencies. The Journal of clinical psychiatry, 1999, Volume: 60, Issue:10 Topics: Acute Disease; Animals; Antipsychotic Agents; Clinical Trials as Topic; Crisis Intervention; Dangero	1999
Atypical antipsychotic medications in the psychiatric emergency service. The Journal of clinical psychiatry, 2000, Volume: 61 Suppl 14 Topics: Administration, Oral; Aggression; Antipsychotic Agents; Benzodiazepines; Drug Administration Schedul	2000
Rationale and guidelines for the inpatient treatment of acute psychosis. The Journal of clinical psychiatry, 2000, Volume: 61 Suppl 14 Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Clozapine; Drug Administration Schedule; Drug	2000
Haloperidol for agitation in dementia. The Cochrane database of systematic reviews, 2001, Issue:4 Topics: Aggression; Anti-Dyskinesia Agents; Dementia; Haloperidol; Humans; Psychomotor Agitation; Randomized	2001
Haloperidol for agitation in dementia. The Cochrane database of systematic reviews, 2002, Issue:2 Topics: Aggression; Anti-Dyskinesia Agents; Dementia; Haloperidol; Humans; Psychomotor Agitation; Randomized	2002
Two types of dopamine receptors in behavioral regulation. Federation proceedings, 1978, Volume: 37, Issue:10 Topics: Animals; Behavior; Behavior, Animal; Benserazide; Brain; Carbidopa; Cats; Dopamine; Haloperidol; Hum	1978
Intravenous haloperidol for tranquilization in critical care patients: a review and critique. AACN clinical issues in critical care nursing, 1991, Volume: 2, Issue:4 Topics: Aged; Basal Ganglia Diseases; Critical Illness; Death, Sudden; Female; Haloperidol; Humans; Infusion	1991
Use of benzodiazepines to control disruptive behavior in inpatients. The Journal of clinical psychiatry, 1988, Volume: 49 Suppl Topics: Aggression; Benzodiazepines; Haloperidol; Hospitalization; Humans; Injections, Intramuscular; Loraze	1988

Article	Year
Cost-Effectiveness of Midazolam Versus Haloperidol Versus Olanzapine for the Management of Acute Agitation in the Accident and Emergency Department. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2022, Volume: 25, Issue:7 Topics: Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Emergency Service, Hospital; Haloperid	2022
An open-label clinical trial of oral transmucosal haloperidol and oral transmucosal olanzapine in the treatment of terminal delirium at home. Trials, 2022, Apr-14, Volume: 23, Issue:1 Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Olanzapine; Psychomotor Agitation	2022
Dexmedetomidine versus haloperidol for sedation of non-intubated patients with hyperactive delirium during the night in a high dependency unit: study protocol for an open-label, parallel-group, randomized controlled trial (DEX-HD trial). BMC anesthesiology, 2023, 06-03, Volume: 23, Issue:1 Topics: Critical Illness; Delirium; Dexmedetomidine; Drugs, Investigational; Haloperidol; Humans; Hypnotics	2023
Efficacy of ketamine for initial control of acute agitation in the emergency department: A randomized study. The American journal of emergency medicine, 2021, Volume: 44 Topics: Adult; Aged; Aged, 80 and over; Anesthetics, Dissociative; Anti-Anxiety Agents; Antipsychotic Agents	2021
Neuroleptic strategies for terminal agitation in patients with cancer and delirium at an acute palliative care unit: a single-centre, double-blind, parallel-group, randomised trial. The Lancet. Oncology, 2020, Volume: 21, Issue:7 Topics: Aged; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Follow-Up Studies; Haloperidol; H	2020
Rapid tranquillisation in a psychiatric emergency hospital in Lebanon: TREC-Lebanon - a pragmatic randomised controlled trial of intramuscular haloperidol and promethazine Psychological medicine, 2022, Volume: 52, Issue:13 Topics: Antipsychotic Agents; Chlorpromazine; Haloperidol; Hospitals, Psychiatric; Humans; Lebanon; Prometha	2022
Association among rescue neuroleptic use, agitation, and perceived comfort: secondary analysis of a randomized clinical trial on agitated delirium. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2021, Volume: 29, Issue:12 Topics: Antipsychotic Agents; Delirium; Double-Blind Method; Haloperidol; Humans; Lorazepam; Psychomotor Agi	2021
Rapid Agitation Control With Ketamine in the Emergency Department: A Blinded, Randomized Controlled Trial. Annals of emergency medicine, 2021, Volume: 78, Issue:6 Topics: Adult; Anesthetics, Dissociative; Canada; Female; Haloperidol; Humans; Hypnotics and Sedatives; Inje	2021
The minimal clinically important difference of the Richmond Agitation-Sedation Scale in patients with cancer with agitated delirium. Cancer, 2018, 05-15, Volume: 124, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Delirium; Drug Therapy, Combination; Female; Haloperidol; Humans; Lo	2018
Rapid agitation control with ketamine in the emergency department (RACKED): a randomized controlled trial protocol. Trials, 2018, Nov-26, Volume: 19, Issue:1 Topics: Adult; Anesthetics, Dissociative; British Columbia; Emergency Service, Hospital; Female; Haloperidol	2018
Intramuscular ziprasidone versus haloperidol for managing agitation in Chinese patients with schizophrenia. Journal of clinical psychopharmacology, 2013, Volume: 33, Issue:2 Topics: Acute Disease; Adult; Antipsychotic Agents; China; Dose-Response Relationship, Drug; Female; Haloper	2013
Intramuscular ziprasidone versus haloperidol for managing agitation in Chinese patients with schizophrenia. Journal of clinical psychopharmacology, 2013, Volume: 33, Issue:2 Topics: Acute Disease; Adult; Antipsychotic Agents; China; Dose-Response Relationship, Drug; Female; Haloper	2013
Intramuscular ziprasidone versus haloperidol for managing agitation in Chinese patients with schizophrenia. Journal of clinical psychopharmacology, 2013, Volume: 33, Issue:2 Topics: Acute Disease; Adult; Antipsychotic Agents; China; Dose-Response Relationship, Drug; Female; Haloper	2013
Intramuscular ziprasidone versus haloperidol for managing agitation in Chinese patients with schizophrenia. Journal of clinical psychopharmacology, 2013, Volume: 33, Issue:2 Topics: Acute Disease; Adult; Antipsychotic Agents; China; Dose-Response Relationship, Drug; Female; Haloper	2013
Morphine is a reasonable alternative to haloperidol in the treatment of postoperative hyperactive-type delirium after cardiac surgery. Journal of cardiothoracic and vascular anesthesia, 2013, Volume: 27, Issue:5 Topics: Aged; Antipsychotic Agents; Cardiac Surgical Procedures; Delirium; Female; Haloperidol; Humans; Male	2013
Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine. Journal of clinical psychopharmacology, 2014, Volume: 34, Issue:1 Topics: Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol;	2014
A naturalistic comparison study of the efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular levomepromazine in acute agitated patients with schizophrenia. Human psychopharmacology, 2014, Volume: 29, Issue:1 Topics: Acute Disease; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Humans; Inje	2014
A double-blind, randomized comparison study of efficacy and safety of intramuscular olanzapine and intramuscular haloperidol in patients with schizophrenia and acute agitated behavior. Journal of clinical psychopharmacology, 2014, Volume: 34, Issue:3 Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Haloperido	2014
Droperidol v. haloperidol for sedation of aggressive behaviour in acute mental health: randomised controlled trial. The British journal of psychiatry : the journal of mental science, 2015, Volume: 206, Issue:3 Topics: Adolescent; Adult; Aged; Aggression; Antipsychotic Agents; Conscious Sedation; Droperidol; Female; H	2015
Efficacy and safety of valproic acid versus haloperidol in patients with acute agitation: results of a randomized, double-blind, parallel-group trial. International clinical psychopharmacology, 2015, Volume: 30, Issue:3 Topics: Adult; Antimanic Agents; Antipsychotic Agents; Basal Ganglia Diseases; Double-Blind Method; Female;	2015
Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: An open-label, randomized controlled trial. Journal of the Formosan Medical Association = Taiwan yi zhi, 2015, Volume: 114, Issue:5 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Female; Haloperidol; Humans	2015
Prehospital Agitation and Sedation Trial (PhAST): A Randomized Control Trial of Intramuscular Haloperidol versus Intramuscular Midazolam for the Sedation of the Agitated or Violent Patient in the Prehospital Environment. Prehospital and disaster medicine, 2015, Volume: 30, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Conscious Sedation; Female; Haloperidol; Human	2015
Preventing ICU Subsyndromal Delirium Conversion to Delirium With Low-Dose IV Haloperidol: A Double-Blind, Placebo-Controlled Pilot Study. Critical care medicine, 2016, Volume: 44, Issue:3 Topics: Administration, Intravenous; Adult; Aged; Antipsychotic Agents; Coma; Critical Illness; Delirium; Do	2016
Dexmedetomidine for the Treatment of Hyperactive Delirium Refractory to Haloperidol in Nonintubated ICU Patients: A Nonrandomized Controlled Trial. Critical care medicine, 2016, Volume: 44, Issue:7 Topics: Aged; Antipsychotic Agents; Cost-Benefit Analysis; Delirium; Dexmedetomidine; Drug Costs; Drug Resis	2016
Comparison of Haloperidol Alone and in Combination with Midazolam for the Treatment of Acute Agitation in an Inpatient Palliative Care Service. Journal of pain & palliative care pharmacotherapy, 2016, Volume: 30, Issue:4 Topics: Aged; Antipsychotic Agents; Drug Therapy, Combination; Female; Haloperidol; Humans; Hypnotics and Se	2016
Outcome in delusional depression comparing trimipramine monotherapy with a combination of amitriptyline and haloperidol--a double-blind multicenter trial. Journal of psychiatric research, 2009, Volume: 43, Issue:7 Topics: Adrenocorticotropic Hormone; Adult; Amitriptyline; Anti-Dyskinesia Agents; Antidepressive Agents, Tr	2009
Dexmedetomidine vs. haloperidol in delirious, agitated, intubated patients: a randomised open-label trial. Critical care (London, England), 2009, Volume: 13, Issue:3 Topics: Adult; Aged; Delirium; Dexmedetomidine; Dopamine Antagonists; Drug-Related Side Effects and Adverse	2009
Dexmedetomidine vs. haloperidol in delirious, agitated, intubated patients: a randomised open-label trial. Critical care (London, England), 2009, Volume: 13, Issue:3 Topics: Adult; Aged; Delirium; Dexmedetomidine; Dopamine Antagonists; Drug-Related Side Effects and Adverse	2009
Dexmedetomidine vs. haloperidol in delirious, agitated, intubated patients: a randomised open-label trial. Critical care (London, England), 2009, Volume: 13, Issue:3 Topics: Adult; Aged; Delirium; Dexmedetomidine; Dopamine Antagonists; Drug-Related Side Effects and Adverse	2009
Dexmedetomidine vs. haloperidol in delirious, agitated, intubated patients: a randomised open-label trial. Critical care (London, England), 2009, Volume: 13, Issue:3 Topics: Adult; Aged; Delirium; Dexmedetomidine; Dopamine Antagonists; Drug-Related Side Effects and Adverse	2009
Comparison of intramuscular olanzapine, orally disintegrating olanzapine tablets, oral risperidone solution, and intramuscular haloperidol in the management of acute agitation in an acute care psychiatric ward in Taiwan. Journal of clinical psychopharmacology, 2010, Volume: 30, Issue:3 Topics: Acute Disease; Administration, Oral; Adult; Benzodiazepines; Disease Management; Female; Haloperidol	2010
Comparison of risperidone orodispersible tablet and intramuscular haloperidol in the treatment of acute psychotic agitation: a randomized open, prospective study. Neuropsychobiology, 2010, Volume: 62, Issue:2 Topics: Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Female; Ha	2010
Effect of aripiprazole versus haloperidol on PANSS Prosocial items in early-episode patients with schizophrenia. Schizophrenia research, 2010, Volume: 120, Issue:1-3 Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Basal Ganglia Dis	2010
Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), 2011, Volume: 33, Issue:1 Topics: Adult; Aggression; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Double-Blind Method; Dru	2011
A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease. International journal of geriatric psychiatry, 2011, Volume: 26, Issue:9 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Double-Blind Method; Female; Halop	2011
Comparison of risperidone oral solution and intramuscular haloperidol with the latter shifting to oral therapy for the treatment of acute agitation in patients with schizophrenia. International clinical psychopharmacology, 2012, Volume: 27, Issue:2 Topics: Administration, Oral; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; China; Clonazepam; Diagn	2012
Acute effects of single-dose aripiprazole and haloperidol on resting cerebral blood flow (rCBF) in the human brain. Human brain mapping, 2013, Volume: 34, Issue:2 Topics: Adolescent; Adult; Algorithms; Antipsychotic Agents; Aripiprazole; Blood Pressure; Brain Mapping; Ce	2013
Akathisia and suicidal ideation in first-episode schizophrenia. Journal of clinical psychopharmacology, 2012, Volume: 32, Issue:5 Topics: Adult; Age Factors; Akathisia, Drug-Induced; Antipsychotic Agents; Depression; Double-Blind Method;	2012
Calming versus sedative effects of intramuscular olanzapine in agitated patients. The American journal of emergency medicine, 2003, Volume: 21, Issue:3 Topics: Adult; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dementia; Doubl	2003
Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients. Psychiatry research, 2003, Jul-15, Volume: 119, Issue:1-2 Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dementia; Dose-Response Relationship, Drug;	2003
Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. BMJ (Clinical research ed.), 2003, Sep-27, Volume: 327, Issue:7417 Topics: Adult; Aggression; Drug Therapy, Combination; Emergency Service, Hospital; Emergency Services, Psych	2003
Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. The Journal of clinical psychiatry, 2004, Volume: 65, Issue:3 Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Cluster Analysis	2004
The tolerability of intramuscular ziprasidone and haloperidol treatment and the transition to oral therapy. International clinical psychopharmacology, 2004, Volume: 19, Issue:1 Topics: Administration, Oral; Adult; Aged; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Inte	2004
Efficacy of accelerated dose titration of olanzapine with adjunctive lorazepam to treat acute agitation in schizophrenia. The American journal of emergency medicine, 2004, Volume: 22, Issue:3 Topics: Acute Disease; Administration, Oral; Adult; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepin	2004
A prospective, double-blind, randomized trial of midazolam versus haloperidol versus lorazepam in the chemical restraint of violent and severely agitated patients. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 2004, Volume: 11, Issue:7 Topics: Adult; Arousal; Blood Pressure; Double-Blind Method; Haloperidol; Heart Rate; Humans; Lorazepam; Mid	2004
Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting. Pragmatic randomised trial of intramuscular lorazepam v. haloperidol plus promethazine. The British journal of psychiatry : the journal of mental science, 2004, Volume: 185 Topics: Antipsychotic Agents; Drug Therapy, Combination; Emergencies; Emergency Service, Hospital; Female; H	2004
Combined therapy with low-potency neuroleptic levomepromazine as an adjunct to haloperidol for agitated patients with acute exacerbation of schizophrenia. European psychiatry : the journal of the Association of European Psychiatrists, 2004, Volume: 19, Issue:6 Topics: Acute Disease; Adult; Antipsychotic Agents; Diagnostic and Statistical Manual of Mental Disorders; D	2004
Olanzapine versus haloperidol in the treatment of agitation in elderly patients with dementia: results of a randomized controlled double-blind trial. Dementia and geriatric cognitive disorders, 2006, Volume: 21, Issue:1 Topics: Aged; Aggression; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Hal	2006
Risperidone versus haloperidol, in combination with lorazepam, in the treatment of acute agitation and psychosis: a pilot, randomized, double-blind, placebo-controlled trial. Journal of psychiatric practice, 2006, Volume: 12, Issue:2 Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Anxiety Agents; Antipsychotic Agents; Double-Blind Meth	2006
Comparative efficacy of risperidone versus haloperidol on behavioural and psychological symptoms of dementia. International journal of geriatric psychiatry, 2006, Volume: 21, Issue:7 Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Anxiety Disorders; Cross-Over Studies; Dementia; Doub	2006
Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2006, Volume: 14, Issue:9 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Brain; Bri	2006
Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology, 2006, Volume: 188, Issue:3 Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Anti-Dyskinesia Agents; Antipsychotic Agents	2006
Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study. Current medical research and opinion, 2006, Volume: 22, Issue:11 Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Halope	2006
Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations. Journal of psychiatric practice, 2007, Volume: 13, Issue:3 Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Do	2007
Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation. Progress in neuro-psychopharmacology & biological psychiatry, 2008, Feb-15, Volume: 32, Issue:2 Topics: Administration, Oral; Adolescent; Adult; Aged; Aggression; Antipsychotic Agents; Basal Ganglia Disea	2008
Rapid tranquillisation in psychiatric emergency settings in India: pragmatic randomised controlled trial of intramuscular olanzapine versus intramuscular haloperidol plus promethazine. BMJ (Clinical research ed.), 2007, Oct-27, Volume: 335, Issue:7625 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Combinations; Emergency Services, Psychiatric; Ha	2007
Rapid tranquillisation in psychiatric emergency settings in Brazil: pragmatic randomised controlled trial of intramuscular haloperidol versus intramuscular haloperidol plus promethazine. BMJ (Clinical research ed.), 2007, Oct-27, Volume: 335, Issue:7625 Topics: Adult; Aggression; Antipsychotic Agents; Drug Combinations; Emergency Services, Psychiatric; Haloper	2007
[Comparative study of the effects of sultopride and haloperidol in agitation states. 94 cases at the psychiatric infirmary of the Paris police headquarters]. La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris, 1983, Jun-23, Volume: 59, Issue:25 Topics: Amisulpride; Haloperidol; Humans; Psychomotor Agitation; Sulpiride	1983
Droperidol vs. haloperidol in the initial management of acutely agitated patients. The Journal of clinical psychiatry, 1984, Volume: 45, Issue:7 Topics: Acute Disease; Adolescent; Adult; Aged; Clinical Trials as Topic; Commitment of Mentally Ill; Danger	1984
Akathisia with haloperidol and thiothixene. Archives of general psychiatry, 1984, Volume: 41, Issue:11 Topics: Adult; Akathisia, Drug-Induced; Anxiety Disorders; Depressive Disorder; Dose-Response Relationship,	1984
Haloperidol, thioridazine and placebo in mentally subnormal patients-serum levels and clinical effects. Acta psychiatrica Scandinavica, 1981, Volume: 63, Issue:3 Topics: Adolescent; Adult; Clinical Trials as Topic; Female; Haloperidol; Humans; Intellectual Disability; M	1981
Effect of carbamazepine on agitation in Alzheimer's inpatients refractory to neuroleptics. The Journal of clinical psychiatry, 1995, Volume: 56, Issue:8 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamazepine; Drug Therapy, Combination; Female; Follow	1995
Rapid tranquilization with intramuscular clonazepam. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 1994, Volume: 39, Issue:7 Topics: Adult; Bipolar Disorder; Clonazepam; Dose-Response Relationship, Drug; Double-Blind Method; Drug Adm	1994
A double-blind randomized clinical trial of rapid tranquilization with I.M. clonazepam and I.M. haloperidol in agitated psychotic patients with manic symptoms. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 1993, Volume: 38 Suppl 4 Topics: Adolescent; Adult; Arousal; Bipolar Disorder; Clonazepam; Double-Blind Method; Drug Therapy, Combina	1993
A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 1997,Winter, Volume: 5, Issue:1 Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Dementia; D	1997
Pilot study of haloperidol, fluoxetine, and placebo for agitation in Alzheimer's disease. The Journal of neuropsychiatry and clinical neurosciences, 1997,Fall, Volume: 9, Issue:4 Topics: Aged; Alzheimer Disease; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Double-Blin	1997
A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. The American journal of psychiatry, 1998, Volume: 155, Issue:11 Topics: Aged; Aggression; Alzheimer Disease; Ambulatory Care; Basal Ganglia Diseases; Brief Psychiatric Rati	1998
Double blind study of tiapride versus haloperidol and placebo in agitation and aggressiveness in elderly patients with cognitive impairment. Psychopharmacology, 2000, Volume: 148, Issue:4 Topics: Aged; Aged, 80 and over; Aggression; Antipsychotic Agents; Cognition Disorders; Double-Blind Method;	2000
Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology, 2000, Nov-14, Volume: 55, Issue:9 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Behavior Therapy; Double-Blind Method; Female; Haloperid	2000
Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia. The Journal of clinical psychiatry, 2001, Volume: 62 Suppl 2 Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Double-	2001
The efficacy of a rapid-acting intramuscular formulation of olanzapine for positive symptoms. The Journal of clinical psychiatry, 2001, Volume: 62 Suppl 2 Topics: Acute Disease; Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric	2001
Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. The American journal of psychiatry, 2001, Volume: 158, Issue:7 Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship,	2001
A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Archives of general psychiatry, 2002, Volume: 59, Issue:5 Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Dose-Response Relatio	2002
No long-term effect of behavioral treatment on psychotropic drug use for agitation in Alzheimer's disease patients. Journal of geriatric psychiatry and neurology, 2002,Summer, Volume: 15, Issue:2 Topics: Aged; Alzheimer Disease; Anti-Anxiety Agents; Antipsychotic Agents; Behavior Therapy; Caregivers; Fe	2002
Loxapine versus haloperidol parenterally in acute psychosis with agitation. A double-blind study. Acta psychiatrica Scandinavica, 1977, Volume: 56, Issue:4 Topics: Acute Disease; Adult; Aged; Aggression; Biperiden; Clinical Trials as Topic; Dibenzoxazepines; Doubl	1977
Relative efficacy of parenteral haloperidol and thiothixene for the emergency treatment of acutely excited and agitated patients. Diseases of the nervous system, 1977, Volume: 38, Issue:12 Topics: Acute Disease; Adult; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation	1977
Adjunctive treatment of manic agitation with lorazepam versus haloperidol: a double-blind study. The Journal of clinical psychiatry, 1992, Volume: 53, Issue:2 Topics: Adult; Aged; Aggression; Bipolar Disorder; Double-Blind Method; Drug Therapy, Combination; Female; H	1992
Side effects during long-term treatment with depot antipsychotic medication. Clinical neuropharmacology, 1991, Volume: 14 Suppl 2 Topics: Akathisia, Drug-Induced; Delayed-Action Preparations; Double-Blind Method; Dyskinesia, Drug-Induced;	1991
Pharmacologic treatment of noncognitive behavioral disturbances in elderly demented patients. The American journal of psychiatry, 1990, Volume: 147, Issue:12 Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Dementia; Diphenhydramine; D	1990
Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. The American journal of psychiatry, 1989, Volume: 146, Issue:12 Topics: Adolescent; Adult; Drug Combinations; Drug Therapy, Combination; Female; Haloperidol; Humans; Inject	1989

Article	Year
Pharmacological evaluation of a diarylmethylene-piperidine derivative: a new potent atypical antipsychotic? Bioorganic & medicinal chemistry letters, 2001, May-21, Volume: 11, Issue:10 Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evalua	2001
Efficacy and safety of intranasal haloperidol in an acute Psychiatry Unit: a pilot study on schizophrenic patients with mild-modedate agitation. Actas espanolas de psiquiatria, 2021, Volume: 49, Issue:5 Topics: Administration, Intranasal; Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Pilot Projec	2021
Midazolam with haloperidol versus lorazepam with haloperidol for agitation: Effect on emergency department lengths of stay. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 2022, Volume: 29, Issue:3 Topics: Antipsychotic Agents; Drug Therapy, Combination; Emergency Service, Hospital; Haloperidol; Humans; L	2022
Olanzapine intramuscular shows better efficacy than zuclopenthixol acetate intramuscular in reducing the need for restraint, but not in comparison to haloperidol intramuscular. International clinical psychopharmacology, 2022, 01-01, Volume: 37, Issue:1 Topics: Antipsychotic Agents; Benzodiazepines; Clopenthixol; Haloperidol; Humans; Injections, Intramuscular;	2022
Prospective study of haloperidol plus lorazepam versus droperidol plus midazolam for the treatment of acute agitation in the emergency department. The American journal of emergency medicine, 2022, Volume: 55 Topics: Antipsychotic Agents; Droperidol; Emergency Service, Hospital; Haloperidol; Humans; Lorazepam; Midaz	2022
Efficacy of Combination Haloperidol, Lorazepam, and Diphenhydramine vs. Combination Haloperidol and Lorazepam in the Treatment of Acute Agitation: A Multicenter Retrospective Cohort Study. The Journal of emergency medicine, 2022, Volume: 62, Issue:4 Topics: Adult; Antipsychotic Agents; Diphenhydramine; Haloperidol; Humans; Hypotension; Lorazepam; Muscarini	2022
Optimal Injectable Haloperidol Dose Assessment in the Older Hospitalized Inpatient. The Annals of pharmacotherapy, 2023, Volume: 57, Issue:6 Topics: Aged; Antipsychotic Agents; Cohort Studies; Haloperidol; Humans; Inpatients; Psychomotor Agitation;	2023
Intravenous Haloperidol Has a Limited Role in the Modern Emergency Department. Annals of emergency medicine, 2023, Volume: 81, Issue:1 Topics: Administration, Intravenous; Antipsychotic Agents; Emergency Service, Hospital; Haloperidol; Humans;	2023
Haloperidol May Be Safely Administered Intravenously in the Emergency Department. Annals of emergency medicine, 2023, Volume: 81, Issue:1 Topics: Antipsychotic Agents; Emergency Service, Hospital; Haloperidol; Humans; Psychomotor Agitation	2023
Acetaminophen improves tardive akathisia induced by dopamine D Journal of pharmacological sciences, 2023, Volume: 151, Issue:1 Topics: Acetaminophen; Akathisia, Drug-Induced; Animals; Antipsychotic Agents; Dopamine; Dopamine D2 Recepto	2023
Acetaminophen improves tardive akathisia induced by dopamine D Journal of pharmacological sciences, 2023, Volume: 151, Issue:1 Topics: Acetaminophen; Akathisia, Drug-Induced; Animals; Antipsychotic Agents; Dopamine; Dopamine D2 Recepto	2023
Acetaminophen improves tardive akathisia induced by dopamine D Journal of pharmacological sciences, 2023, Volume: 151, Issue:1 Topics: Acetaminophen; Akathisia, Drug-Induced; Animals; Antipsychotic Agents; Dopamine; Dopamine D2 Recepto	2023
Acetaminophen improves tardive akathisia induced by dopamine D Journal of pharmacological sciences, 2023, Volume: 151, Issue:1 Topics: Acetaminophen; Akathisia, Drug-Induced; Animals; Antipsychotic Agents; Dopamine; Dopamine D2 Recepto	2023
Comparison of Droperidol and Midazolam Versus Haloperidol and Lorazepam for Acute Agitation Management in the Emergency Department. The Annals of pharmacotherapy, 2023, Volume: 57, Issue:12 Topics: Antipsychotic Agents; Droperidol; Emergency Service, Hospital; Haloperidol; Humans; Injections, Intr	2023
Involuntary movements in an adolescent: what are the causes? BMJ case reports, 2019, Dec-10, Volume: 12, Issue:12 Topics: Adolescent; Alcoholic Intoxication; Antipsychotic Agents; Biperiden; Dystonia; Emergency Service, Ho	2019
Mindful Melody: feasibility of implementing music listening on an inpatient psychiatric unit and its relation to the use of as needed medications for acute agitation. BMC psychiatry, 2021, 03-06, Volume: 21, Issue:1 Topics: Anxiety; Feasibility Studies; Haloperidol; Humans; Inpatients; Music; Psychomotor Agitation	2021
Pseudodelirium: Psychiatric Conditions to Consider on the Differential for Delirium. The Journal of neuropsychiatry and clinical neurosciences, 2021,Fall, Volume: 33, Issue:4 Topics: Antipsychotic Agents; Brief Psychiatric Rating Scale; Catatonia; Delirium; Diagnosis, Differential;	2021
'Palliative sedation'? A retrospective cohort study on the use and labelling of continuously administered sedatives on a palliative care unit. Palliative medicine, 2018, Volume: 32, Issue:7 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Conscious Sedatio	2018
Trends in pharmacological emergency treatment of patients suffering from schizophrenia over a 16-year observation period. International clinical psychopharmacology, 2018, Volume: 33, Issue:4 Topics: Adult; Antipsychotic Agents; Austria; Benzodiazepines; Emergency Treatment; Female; Haloperidol; Hos	2018
Parenteral Antipsychotic Choice and Its Association With Emergency Department Length of Stay for Acute Agitation Secondary to Alcohol Intoxication. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 2019, Volume: 26, Issue:1 Topics: Adult; Alcoholic Intoxication; Antipsychotic Agents; Droperidol; Drug Delivery Systems; Emergency Se	2019
Intramuscular Midazolam, Olanzapine, Ziprasidone, or Haloperidol for Treating Acute Agitation in the Emergency Department. Annals of emergency medicine, 2018, Volume: 72, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Cohort Studies; Emergency Medical	2018
Intermittent Administration of Haloperidol after Cortical Impact Injury Neither Impedes Spontaneous Recovery Nor Attenuates the Efficacy of Environmental Enrichment. Journal of neurotrauma, 2019, 05-15, Volume: 36, Issue:10 Topics: Animals; Antipsychotic Agents; Brain Injuries, Traumatic; Haloperidol; Housing, Animal; Male; Psycho	2019
Study Enrollment When "Preconsent" Is Utilized for a Randomized Clinical Trial of Two Treatments for Acute Agitation in the Emergency Department. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 2019, Volume: 26, Issue:5 Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Emergency Service, Hospital; Ethics, Research; Female	2019
Rescue Sedation When Treating Acute Agitation in the Emergency Department With Intramuscular Antipsychotics. The Journal of emergency medicine, 2019, Volume: 56, Issue:5 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Droperidol; Emergency Service, Hospital; Female; Halop	2019
Discussions about palliative sedation in hospice: Frequency, timing and factors associated with patient involvement. European journal of cancer care, 2019, Volume: 28, Issue:3 Topics: Aged; Aged, 80 and over; Analgesics, Opioid; Antipsychotic Agents; Decision Making, Shared; Delirium	2019
First generation antipsychotic-induced severe hypothermia: A case report and review of the literature. Asian journal of psychiatry, 2019, Volume: 44 Topics: Antipsychotic Agents; Chlorpromazine; Diagnosis, Differential; Drug Administration Schedule; Female;	2019
Agreement between ICU clinicians and electrophysiology cardiologists on the decision to initiate a QTc-interval prolonging medication in critically ill patients with potential risk factors for torsade de pointes: a comparative, case-based evaluation. Pharmacotherapy, 2013, Volume: 33, Issue:6 Topics: Antipsychotic Agents; Critical Illness; Decision Making; Delirium; Haloperidol; Health Care Surveys;	2013
Haloperidol overdosing in the treatment of agitated hospitalized older people with delirium: a retrospective chart review from a community teaching hospital. Drugs & aging, 2013, Volume: 30, Issue:8 Topics: Aged; Aged, 80 and over; Aging; Anti-Anxiety Agents; Delirium; Dopamine Antagonists; Dose-Response R	2013
Stability of intraocular pressure after retinal reattachment surgery during electroconvulsive therapy for intractable self-injury in a 12-year-old autistic boy. The journal of ECT, 2014, Volume: 30, Issue:1 Topics: Aggression; Anticonvulsants; Antipsychotic Agents; Autistic Disorder; Child; Electroconvulsive Thera	2014
High-dose neuroleptics and neuroleptic rotation for agitated delirium near the end of life. The American journal of hospice & palliative care, 2014, Volume: 31, Issue:8 Topics: Adult; Antipsychotic Agents; Delirium; Drug Substitution; Female; Gastrointestinal Neoplasms; Halope	2014
Is the use of haloperidol a safe and effective method of tranquilization for patients with psychosis-induced aggression or agitation? Annals of emergency medicine, 2014, Volume: 63, Issue:6 Topics: Aggression; Antipsychotic Agents; Haloperidol; Humans; Psychomotor Agitation; Psychotic Disorders	2014
How is agitation and restlessness managed in the last 24 h of life in patients whose care is supported by the Liverpool care pathway for the dying patient? BMJ supportive & palliative care, 2011, Volume: 1, Issue:3 Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Cohort Studies; Critical Pathways; Female; Haloperido	2011
[Emergency psychopharmacotherapy in Hungary -- preliminary data]. Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, 2014, Volume: 16, Issue:1 Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clopenthixol; Droperidol; Drug Prescript	2014
Differential effects of intermittent versus continuous haloperidol treatment throughout adolescence on haloperidol sensitization and social behavior in adulthood. Progress in neuro-psychopharmacology & biological psychiatry, 2014, Oct-03, Volume: 54 Topics: Aging; Animals; Antipsychotic Agents; Avoidance Learning; Drug Delivery Systems; Haloperidol; Male;	2014
Involvement of cholinergic system in hyperactivity in dopamine-deficient mice. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2015, Mar-13, Volume: 40, Issue:5 Topics: Acetylcholine; Akathisia, Drug-Induced; Animals; Anti-Dyskinesia Agents; Antipsychotic Agents; Centr	2015
Discontinuing the Use of PRN Intramuscular Medication for Agitation in an Acute Psychiatric Hospital. The Psychiatric quarterly, 2016, Volume: 87, Issue:1 Topics: Administration, Oral; Adult; Diphenhydramine; Drug Utilization; Female; Haloperidol; Hospitals, Psyc	2016
A Protocol for the Control of Agitation in Palliative Care. The American journal of hospice & palliative care, 2016, Volume: 33, Issue:10 Topics: Aged; Aged, 80 and over; Clinical Protocols; Drug Administration Routes; Drug Administration Schedul	2016
Managing Care of an Intrapartum Patient with Agitation and Psychosis: Ethical and Legal Implications. AMA journal of ethics, 2016, Mar-01, Volume: 18, Issue:3 Topics: Adult; Antipsychotic Agents; Cesarean Section; Decision Making; Ethical Analysis; Ethics Consultatio	2016
Syndrome of Inappropriate Antidiuretic Hormone in a Patient Receiving High-Dose Haloperidol and Quetiapine Therapy. The Journal of neuropsychiatry and clinical neurosciences, 2016,Spring, Volume: 28, Issue:2 Topics: Adult; Haloperidol; Humans; Inappropriate ADH Syndrome; Male; Psychomotor Agitation; Quetiapine Fuma	2016
A prospective study of ketamine versus haloperidol for severe prehospital agitation. Clinical toxicology (Philadelphia, Pa.), 2016, Volume: 54, Issue:7 Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Dose-Response Relationship, Drug; Emergency Service,	2016
Treatment of agitation in the acute psychiatric setting. An observational study of the effectiveness of intramuscular psychotropic medication. Nordic journal of psychiatry, 2016, Volume: 70, Issue:8 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Female; Haloperidol; Humans; Injec	2016
Look again at psychedelic drugs. Nursing standard (Royal College of Nursing (Great Britain) : 1987), 2016, Jun-29, Volume: 30, Issue:44 Topics: Anxiety; Delirium; Depression; Diazepam; Hallucinogens; Haloperidol; Humans; Lorazepam; Midazolam; P	2016
Antipsychotic Selection for Acute Agitation and Time to Repeat Use in a Psychiatric Emergency Department. Journal of psychiatric practice, 2016, Volume: 22, Issue:6 Topics: Adult; Antipsychotic Agents; Emergency Services, Psychiatric; Female; Haloperidol; Humans; Length of	2016
Neuroleptic malignant syndrome and cardiac surgery. A case report. The Journal of cardiovascular surgery, 2008, Volume: 49, Issue:5 Topics: Aged; Antipsychotic Agents; Cardiac Surgical Procedures; Diagnosis, Differential; Haloperidol; Human	2008
Chronic administration of antipsychotics impede behavioral recovery after experimental traumatic brain injury. Neuroscience letters, 2008, Dec-31, Volume: 448, Issue:3 Topics: Aggression; Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; Brain Injuries; H	2008
Intramuscular olanzapine versus short-acting typical intramuscular antipsychotics: comparison of real-life effectiveness in the treatment of agitation. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2009, Volume: 10, Issue:1 Topics: Acute Disease; Administration, Oral; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiaze	2009
Reversal of haloperidol-induced cardiac arrest by using lipid emulsion. Annals of internal medicine, 2009, May-19, Volume: 150, Issue:10 Topics: Anti-Dyskinesia Agents; Fat Emulsions, Intravenous; Female; Haloperidol; Heart Arrest; Humans; Middl	2009
Tackling agitated delirium--the tip of the iceberg. Critical care (London, England), 2009, Volume: 13, Issue:3 Topics: Antipsychotic Agents; Delirium; Dexmedetomidine; Haloperidol; Humans; Hypnotics and Sedatives; Psych	2009
Intramuscular haloperidol versus intramuscular olanzapine for treatment of acute agitation: a cost-minimization study. Pharmacotherapy, 2009, Volume: 29, Issue:8 Topics: Acute Disease; Adult; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Cholinergic Antago	2009
An intoxicated man with facial trauma. Internal and emergency medicine, 2010, Volume: 5, Issue:2 Topics: Aggression; Alcoholic Intoxication; Anti-Anxiety Agents; Antipsychotic Agents; Emergency Medical Ser	2010
Comparison of short-acting intramuscular antipsychotic medication: impact on length of stay and cost. American journal of therapeutics, 2011, Volume: 18, Issue:4 Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cohort Studies; Drug Costs; Female; Halo	2011
Akathisia after mild traumatic head injury. Journal of neurosurgery. Pediatrics, 2010, Volume: 5, Issue:5 Topics: Accidental Falls; Adolescent; Akathisia, Drug-Induced; Antipsychotic Agents; Athletic Injuries; Bicy	2010
Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 3. Rapid tranquilisation in acute psychotic agitation. Emergency medicine journal : EMJ, 2011, Volume: 28, Issue:1 Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Emergencies; Emergency Medicine; Emergency Ser	2011
A comparison of the safety of olanzapine and haloperidol in combination with benzodiazepines in emergency department patients with acute agitation. The Journal of emergency medicine, 2012, Volume: 43, Issue:5 Topics: Acute Disease; Adult; Alcoholic Intoxication; Analysis of Variance; Antipsychotic Agents; Benzodiaze	2012
Additional use of methotrimeprazine for treating refractory agitation in pediatric patients. Intensive care medicine, 2012, Volume: 38, Issue:1 Topics: Adolescent; Analgesics, Non-Narcotic; Benzodiazepines; Child, Preschool; Drug Therapy, Combination;	2012
A protocol for the acute control of agitation in palliative care: a preliminary report. The American journal of hospice & palliative care, 2012, Volume: 29, Issue:7 Topics: Antipsychotic Agents; Clinical Protocols; Drug Therapy, Combination; Haloperidol; Humans; Hypnotics	2012
A naturalistic study of intramuscular haloperidol versus intramuscular olanzapine for the management of acute agitation. Journal of clinical psychopharmacology, 2012, Volume: 32, Issue:3 Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Drug	2012
A computerized physician order entry set designed to improve safety of intravenous haloperidol utilization: a retrospective study in agitated hospitalized patients. Drug safety, 2012, Sep-01, Volume: 35, Issue:9 Topics: Aged; Antipsychotic Agents; Cohort Studies; Death, Sudden, Cardiac; Electrocardiography; Female; Hal	2012
Use of haloperidol in PCP-intoxicated individuals. Clinical toxicology (Philadelphia, Pa.), 2012, Volume: 50, Issue:9 Topics: Adult; Electrocardiography; Female; Haloperidol; Humans; Male; Middle Aged; Phencyclidine; Psychomot	2012
Four essential drugs needed for quality care of the dying: a Delphi-study based international expert consensus opinion. Journal of palliative medicine, 2013, Volume: 16, Issue:1 Topics: Adult; Aged; Analgesics, Opioid; Anti-Anxiety Agents; Antipsychotic Agents; Delphi Technique; Drugs,	2013
Consensus statement on the use of intramuscular aripiprazole for the rapid control of agitation in bipolar mania and schizophrenia. Current medical research and opinion, 2013, Volume: 29, Issue:3 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Haloperidol; Humans; Hypnotic	2013
TREC-Rio trial: a randomised controlled trial for rapid tranquillisation for agitated patients in emergency psychiatric rooms [ISRCTN44153243]. BMC psychiatry, 2002, Oct-16, Volume: 2 Topics: Brazil; Clinical Protocols; Drug Combinations; Emergency Services, Psychiatric; Ethics, Research; Ha	2002
Viral encephalitis complicated by neuroleptic malignant syndrome in a 7-year-old girl. Pediatric emergency care, 2003, Volume: 19, Issue:2 Topics: Anticonvulsants; Carbidopa; Child; Dopamine Agents; Drug Therapy, Combination; Encephalitis, Viral;	2003
A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia. Clinical therapeutics, 2003, Volume: 25, Issue:2 Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Data Collection; Dibenzothiazep	2003
Early recognition of neuroleptic malignant syndrome during traumatic brain injury rehabilitation. Brain injury, 2003, Volume: 17, Issue:7 Topics: Adult; Anti-Dyskinesia Agents; Antipsychotic Agents; Brain Injuries; Haloperidol; Humans; Male; Neur	2003
[R-1625: a new drug for the symptomatic treatment of psychomotor excitation]. Acta neurologica et psychiatrica Belgica, 1958, Volume: 58, Issue:10 Topics: Haloperidol; Humans; Hypnotics and Sedatives; Psychomotor Agitation	1958
Efficacy of risperidone in treating the hyperactive symptoms of delirium. International clinical psychopharmacology, 2004, Volume: 19, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Dose-Response Relationship, Drug; Fe	2004
Beyond haloperidol: teaching emergency medicine residents to manage acute agitation and aggression in the emergency department. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2004, Volume: 49, Issue:8 Topics: Acute Disease; Aggression; Antipsychotic Agents; Emergency Medical Services; Emergency Medicine; Hal	2004
Neuroleptic malignant syndrome and clozapine withdrawal at the same time? Progress in neuro-psychopharmacology & biological psychiatry, 2005, Volume: 29, Issue:1 Topics: Adult; Antipsychotic Agents; Clozapine; Haloperidol; Humans; Male; Neuroleptic Malignant Syndrome; P	2005
Haloperidol use is associated with lower hospital mortality in mechanically ventilated patients. Critical care medicine, 2005, Volume: 33, Issue:1 Topics: Adult; Aged; Antipsychotic Agents; Cohort Studies; Conscious Sedation; Critical Care; Critical Illne	2005
Haloperidol use is associated with lower hospital mortality in mechanically ventilated patients. Critical care medicine, 2005, Volume: 33, Issue:1 Topics: Adult; Aged; Antipsychotic Agents; Cohort Studies; Conscious Sedation; Critical Care; Critical Illne	2005
Haloperidol use is associated with lower hospital mortality in mechanically ventilated patients. Critical care medicine, 2005, Volume: 33, Issue:1 Topics: Adult; Aged; Antipsychotic Agents; Cohort Studies; Conscious Sedation; Critical Care; Critical Illne	2005
Haloperidol use is associated with lower hospital mortality in mechanically ventilated patients. Critical care medicine, 2005, Volume: 33, Issue:1 Topics: Adult; Aged; Antipsychotic Agents; Cohort Studies; Conscious Sedation; Critical Care; Critical Illne	2005
Haloperidol use is associated with lower hospital mortality in mechanically ventilated patients. Critical care medicine, 2005, Volume: 33, Issue:1 Topics: Adult; Aged; Antipsychotic Agents; Cohort Studies; Conscious Sedation; Critical Care; Critical Illne	2005
Haloperidol use is associated with lower hospital mortality in mechanically ventilated patients. Critical care medicine, 2005, Volume: 33, Issue:1 Topics: Adult; Aged; Antipsychotic Agents; Cohort Studies; Conscious Sedation; Critical Care; Critical Illne	2005
Haloperidol use is associated with lower hospital mortality in mechanically ventilated patients. Critical care medicine, 2005, Volume: 33, Issue:1 Topics: Adult; Aged; Antipsychotic Agents; Cohort Studies; Conscious Sedation; Critical Care; Critical Illne	2005
Haloperidol use is associated with lower hospital mortality in mechanically ventilated patients. Critical care medicine, 2005, Volume: 33, Issue:1 Topics: Adult; Aged; Antipsychotic Agents; Cohort Studies; Conscious Sedation; Critical Care; Critical Illne	2005
Haloperidol use is associated with lower hospital mortality in mechanically ventilated patients. Critical care medicine, 2005, Volume: 33, Issue:1 Topics: Adult; Aged; Antipsychotic Agents; Cohort Studies; Conscious Sedation; Critical Care; Critical Illne	2005
Agitation in the critically ill patient: a marker of health or a plea for treatment? Critical care medicine, 2005, Volume: 33, Issue:1 Topics: Antipsychotic Agents; Conscious Sedation; Critical Care; Critical Illness; Delirium; Haloperidol; Ho	2005
Auditory hallucinations after right temporal gyri resection. The Journal of neuropsychiatry and clinical neurosciences, 2005,Spring, Volume: 17, Issue:2 Topics: Adult; Affect; Anticonvulsants; Antipsychotic Agents; Brain Injuries; Carbamazepine; Electroencephal	2005
Regression to the mean: implications for clinical trials of psychotropic agents in dementia. Current Alzheimer research, 2004, Volume: 1, Issue:4 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Behavior Therapy; Data Interpretat	2004
A retrospective study of the safety of intramuscular ziprasidone in agitated elderly patients. The Journal of clinical psychiatry, 2005, Volume: 66, Issue:7 Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Arrhythmias, Cardiac; Dementia; Electrocardiography;	2005
A post hoc analysis of transitioning to oral treatment with olanzapine or haloperidol after 24-hour intramuscular treatment in acutely agitated adult patients with schizophrenia. Clinical therapeutics, 2005, Volume: 27, Issue:10 Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Humans; Inj	2005
An unusual case of subterfuge in the emergency department: covert administration of antipsychotic and anxiolytic medications to control an agitated patient. Annals of emergency medicine, 2006, Volume: 47, Issue:1 Topics: Administration, Oral; Adult; Anti-Anxiety Agents; Antipsychotic Agents; Beverages; Bipolar Disorder;	2006
Naturalistic study of intramuscular ziprasidone versus conventional agents in agitated elderly patients: retrospective findings from a psychiatric emergency service. The American journal of geriatric pharmacotherapy, 2005, Volume: 3, Issue:4 Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Databases, Factual; Emergency Medical Services; Emerg	2005
Anabolic androgenic steroid abuse and mood disorder: a case report. The international journal of neuropsychopharmacology, 2007, Volume: 10, Issue:2 Topics: Adult; Anabolic Agents; Antipsychotic Agents; Bipolar Disorder; Haloperidol; Humans; Impulsive Behav	2007
Intramuscular aripiprazole in the control of agitation. Journal of psychiatric practice, 2007, Volume: 13, Issue:3 Topics: Adult; Antipsychotic Agents; Aripiprazole; Arousal; Bipolar Disorder; Dose-Response Relationship, Dr	2007
Pre-emptive use of haloperidol in ICU to prevent emergence agitation. Anaesthesia, 2007, Volume: 62, Issue:7 Topics: Adult; Anti-Dyskinesia Agents; Conscious Sedation; Critical Care; Haloperidol; Humans; Male; Psychom	2007
Multiple medication use presenting as Parkinson's dementia complex: a message from Titanic. Journal of psychiatric practice, 2008, Volume: 14, Issue:1 Topics: Aged; Anti-Infective Agents; Antiparkinson Agents; Antipsychotic Agents; Bacteriuria; Ciprofloxacin;	2008
Fasciculations after rattlesnake envenomations: a retrospective statewide poison control system study. Clinical toxicology (Philadelphia, Pa.), 2008, Volume: 46, Issue:2 Topics: Adolescent; Adult; Animals; Antivenins; Anxiety; California; Child; Child, Preschool; Crotalus; Data	2008
Development of tolerance to the therapeutic effect of amantadine on akathisia. Journal of clinical psychopharmacology, 1984, Volume: 4, Issue:4 Topics: Adult; Akathisia, Drug-Induced; Amantadine; Bipolar Disorder; Drug Tolerance; Female; Haloperidol; H	1984
[Biochemical and psychophysiological study of haloperidol-induced akathisia]. Yakubutsu, seishin, kodo = Japanese journal of psychopharmacology, 1983, Volume: 3, Issue:1 Topics: Action Potentials; Adult; Akathisia, Drug-Induced; Autonomic Nervous System; Emotions; Haloperidol;	1983
Automated analysis of stereotypic behavior induced by psychomotor stimulants. Pharmacology, biochemistry, and behavior, 1983, Volume: 19, Issue:1 Topics: Amphetamine; Animals; Apomorphine; Autoanalysis; Drug Interactions; Haloperidol; Humans; Male; Metho	1983
Response to antipsychotic medication: the doctor's and the consumer's view. The American journal of psychiatry, 1984, Volume: 141, Issue:1 Topics: Adult; Akathisia, Drug-Induced; Attitude of Health Personnel; Attitude to Health; Basal Ganglia Dise	1984
Cellulitis and agitation: a diagnostic dilemma. Hospital practice (Office ed.), 1982, Volume: 17, Issue:9 Topics: Cellulitis; Diagnosis, Differential; Haloperidol; Humans; Infections; Male; Middle Aged; Psychomotor	1982
Cellulitis and agitation: the haloperidol effect. Hospital practice (Office ed.), 1982, Volume: 17, Issue:11 Topics: Cellulitis; Haloperidol; Humans; Psychomotor Agitation; Thyrotropin; Thyrotropin-Releasing Hormone;	1982
Akathisia: an overlooked, distressing, but treatable condition. The Journal of nervous and mental disease, 1981, Volume: 169, Issue:9 Topics: Akathisia, Drug-Induced; Antiparkinson Agents; Female; Haloperidol; Humans; Middle Aged; Psychomotor	1981
Continuous infusions of haloperidol in critically ill patients. Critical care medicine, 1995, Volume: 23, Issue:1 Topics: Critical Illness; Haloperidol; Humans; Infusions, Intravenous; Psychomotor Agitation	1995
Continuous infusion of haloperidol in agitated, critically ill patients. Critical care medicine, 1994, Volume: 22, Issue:3 Topics: Critical Illness; Haloperidol; Humans; Infusions, Intravenous; Psychomotor Agitation; Torsades de Po	1994
Continuous infusion of haloperidol controls agitation in critically ill patients. Critical care medicine, 1994, Volume: 22, Issue:3 Topics: Adolescent; Adult; Clinical Protocols; Conscious Sedation; Critical Illness; Female; Haloperidol; Hu	1994
Prolongation of the corrected QT and torsades de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill. Journal of clinical psychopharmacology, 1993, Volume: 13, Issue:2 Topics: Adult; Alcoholism; Cardiomyopathy, Dilated; Delirium; Dose-Response Relationship, Drug; Electrocardi	1993
Continuous infusion of haloperidol. The American journal of psychiatry, 1993, Volume: 150, Issue:4 Topics: Aged; Critical Care; Delirium; Female; Haloperidol; Humans; Infusions, Intravenous; Male; Middle Age	1993
Neuroleptic malignant syndrome in communicating hydrocephaly and microcephaly. Journal of clinical psychopharmacology, 1993, Volume: 13, Issue:1 Topics: Aged; Confusion; Drug Administration Schedule; Female; Haloperidol; Humans; Hydrocephalus; Microceph	1993
Managing agitated patients in a general hospital. The Western journal of medicine, 1996, Volume: 164, Issue:3 Topics: Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Psychomotor Agitation	1996
Gabapentin for behavioral agitation in Alzheimer's disease. Journal of clinical psychopharmacology, 1997, Volume: 17, Issue:1 Topics: Acetates; Aged; Alzheimer Disease; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Admini	1997
Acutely agitated patients: a comparison of the use of haloperidol and droperidol in the emergency department. Journal of emergency nursing, 1997, Volume: 23, Issue:6 Topics: Antipsychotic Agents; Droperidol; Haloperidol; Humans; Patient Compliance; Patient Education as Topi	1997
Propranolol attenuates haloperidol-induced Fos expression in discrete regions of rat brain: possible brain regions responsible for akathisia. Brain research, 1998, Aug-17, Volume: 802, Issue:1-2 Topics: Adrenergic beta-Antagonists; Animals; Antipsychotic Agents; Brain; Brain Mapping; Drug Combinations;	1998
Neuroleptic malignant syndrome in a burn patient. Burns : journal of the International Society for Burn Injuries, 1998, Volume: 24, Issue:6 Topics: Accidents, Occupational; Adult; Antipsychotic Agents; Bromocriptine; Burns; Dantrolene; Debridement;	1998
Frequency, severity, and treatment of agitation in young versus elderly patients in the ICU. Pharmacotherapy, 2000, Volume: 20, Issue:1 Topics: Adult; Age Factors; Aged; Analgesics, Opioid; Anti-Anxiety Agents; Antipsychotic Agents; APACHE; Coh	2000
Torsades de pointes secondary to intravenous haloperidol after coronary bypass grafting surgery. Canadian journal of anaesthesia = Journal canadien d'anesthesie, 2000, Volume: 47, Issue:3 Topics: Anti-Dyskinesia Agents; Antipsychotic Agents; Coronary Artery Bypass; Critical Care; Delirium; Elect	2000
Evaluating the usage of droperidol in acutely agitated persons with brain injury. Brain injury, 2000, Volume: 14, Issue:3 Topics: Adult; Antipsychotic Agents; Brain Injuries; Diphenhydramine; Droperidol; Female; Haloperidol; Human	2000
Corrected QT interval prolongation associated with intravenous haloperidol in acute coronary syndromes. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2000, Volume: 50, Issue:3 Topics: Aged; Angina, Unstable; Antipsychotic Agents; Arrhythmias, Cardiac; Electrocardiography; Haloperidol	2000
Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. The Journal of clinical psychiatry, 2001, Volume: 62, Issue:3 Topics: Acute Disease; Administration, Oral; Adult; Antipsychotic Agents; Drug Therapy, Combination; Emergen	2001
The association between intravenous haloperidol and prolonged QT interval. Journal of clinical psychopharmacology, 2001, Volume: 21, Issue:3 Topics: Adult; Anti-Anxiety Agents; Antipsychotic Agents; Cohort Studies; Confidence Intervals; Cross-Sectio	2001
Neuroleptic malignant syndrome with hypotonia: a diagnostic challenge. European neurology, 2001, Volume: 46, Issue:1 Topics: Adult; Anti-Dyskinesia Agents; Haloperidol; Humans; Male; Muscle Hypotonia; Neuroleptic Malignant Sy	2001
Neuroleptic malignant syndrome in pregnancy. Obstetrics and gynecology, 2001, Volume: 98, Issue:5 Pt 2 Topics: Antipsychotic Agents; Female; Haloperidol; Humans; Neuroleptic Malignant Syndrome; Pneumonia, Viral;	2001
Failed challenge with quetiapine after neuroleptic malignant syndrome with conventional antipsychotics. Pharmacotherapy, 2001, Volume: 21, Issue:8 Topics: Alzheimer Disease; Antipsychotic Agents; Chlorpromazine; Dibenzothiazepines; Haloperidol; Humans; Hy	2001
Shifting from haloperidol to risperidone for behavioral disturbances in dementia: safety, response predictors, and mood effects. Journal of clinical psychopharmacology, 2002, Volume: 22, Issue:1 Topics: Activities of Daily Living; Affect; Aged; Alzheimer Disease; Antipsychotic Agents; Dementia, Vascula	2002
Current practices in managing acutely disturbed patients at three hospitals in Rio de Janeiro-Brazil: a prevalence study. BMC psychiatry, 2002, Volume: 2 Topics: Aggression; Benzodiazepines; Brazil; Clinical Protocols; Drug Combinations; Drug Utilization; Emerge	2002
Prevention of relapse in schizophrenia. The New England journal of medicine, 2002, May-02, Volume: 346, Issue:18 Topics: Antipsychotic Agents; Haloperidol; Humans; Hyperkinesis; Psychomotor Agitation; Risperidone; Schizop	2002
Treatment of the agitated patient with an organic brain disorder. JAMA, 1978, Jul-28, Volume: 240, Issue:4 Topics: Adult; Aged; Antipsychotic Agents; Brain Damage, Chronic; Brain Diseases; Brain Injuries; Haloperido	1978
Behavioral and neuroendocrine effects of low dose ET-495: antagonism by haloperidol. Journal of neural transmission, 1979, Volume: 44, Issue:4 Topics: Adult; Dose-Response Relationship, Drug; Growth Hormone; Haloperidol; Humans; Male; Middle Aged; Nau	1979
[Intravenous haloperidol (Serenase) in treatment of severe psychomotor agitation]. Ugeskrift for laeger, 1979, Dec-03, Volume: 141, Issue:49 Topics: Adolescent; Adult; Female; Haloperidol; Humans; Injections, Intramuscular; Injections, Intravenous;	1979
The use of haloperidol to control agitation/violence during admission to an alcohol detoxification center. Currents in alcoholism, 1979, Volume: 7 Topics: Alcoholic Intoxication; Behavior; Female; Haloperidol; Humans; Male; Psychomotor Agitation; Violence	1979
[Combined haloperidol and scopolamine for tranquilization of extremely restless patients]. Harefuah, 1978, Jun-15, Volume: 94, Issue:12 Topics: Barbiturates; Drug Combinations; Haloperidol; Humans; Psychomotor Agitation; Scopolamine; Substance-	1978
Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol. Psychopharmacology, 1992, Volume: 106, Issue:4 Topics: Adult; Akathisia, Drug-Induced; Brain; Brain Chemistry; Haloperidol; Humans; Male; Prolactin; Psycho	1992
Psychotic behavior after right hemispheric cerebrovascular accident: a case report. Archives of physical medicine and rehabilitation, 1992, Volume: 73, Issue:4 Topics: Brain; Cerebral Infarction; Delusions; Haloperidol; Humans; Male; Mental Status Schedule; Middle Age	1992
Brachial plexus palsy with the use of haloperidol and a geriatric chair. DICP : the annals of pharmacotherapy, 1991, Volume: 25, Issue:10 Topics: Aged; Aged, 80 and over; Brachial Plexus; Haloperidol; Humans; Male; Muscle Spasticity; Nursing Home	1991
Neurologic approach to drug-induced movement disorders: a study of 125 patients. Southern medical journal, 1990, Volume: 83, Issue:5 Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Amitriptyline; Antipsychotic Agents; Chorea	1990
Neuroleptic malignant syndrome with intravenous haloperidol. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 1990, Volume: 35, Issue:9 Topics: Adult; Haloperidol; Humans; Male; Neurocognitive Disorders; Neuroleptic Malignant Syndrome; Psychomo	1990
Treatment of acute nonspecific delirium with i.v. haloperidol in surgical intensive care patients. Acta anaesthesiologica Belgica, 1989, Volume: 40, Issue:3 Topics: Acute Disease; Aged; Delirium; Female; Haloperidol; Humans; Infusions, Intravenous; Male; Postoperat	1989
Akathisia: the syndrome of motor restlessness. American family physician, 1987, Volume: 35, Issue:2 Topics: Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Diphenhydramine; Haloperidol; Humans; Ma	1987
Very low-dose neuroleptic treatment in two patients with agitation associated with Alzheimer's disease. The Journal of clinical psychiatry, 1987, Volume: 48, Issue:5 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Haloperidol; Humans; Male; Middle	1987
Fatal central effects of diazepam potentiated by alcohol and haldol. Acta medicinae legalis et socialis, 1985, Volume: 35, Issue:1 Topics: Alcoholic Intoxication; Diazepam; Drug Synergism; Drug Therapy, Combination; Ethanol; Haloperidol; H	1985
Agitation associated with dementia: neuroleptic malignant syndrome and fatal outcome in an 84-year-old man. Journal of clinical psychopharmacology, 1988, Volume: 8, Issue:6 Topics: Aged; Aged, 80 and over; Dementia; Dose-Response Relationship, Drug; Haloperidol; Humans; Male; Neur	1988
Treatment of severe, refractory agitation with a haloperidol drip. The Journal of clinical psychiatry, 1988, Volume: 49, Issue:6 Topics: Acute Disease; Cerebral Infarction; Delirium; Female; Haloperidol; Humans; Infusions, Intravenous; M	1988
Tardive akathisia associated with low-dose haloperidol use. Journal of clinical psychopharmacology, 1987, Volume: 7, Issue:3 Topics: Akathisia, Drug-Induced; Female; Haloperidol; Humans; Middle Aged; Psychomotor Agitation	1987
Agitated behaviors in the elderly. II. Preliminary results in the cognitively deteriorated. Journal of the American Geriatrics Society, 1986, Volume: 34, Issue:10 Topics: Activities of Daily Living; Aged; Aggression; Cognition Disorders; Confusion; Female; Haloperidol; H	1986
Agitated behaviors in the elderly. II. Preliminary results in the cognitively deteriorated. Journal of the American Geriatrics Society, 1986, Volume: 34, Issue:10 Topics: Activities of Daily Living; Aged; Aggression; Cognition Disorders; Confusion; Female; Haloperidol; H	1986
Agitated behaviors in the elderly. II. Preliminary results in the cognitively deteriorated. Journal of the American Geriatrics Society, 1986, Volume: 34, Issue:10 Topics: Activities of Daily Living; Aged; Aggression; Cognition Disorders; Confusion; Female; Haloperidol; H	1986
Agitated behaviors in the elderly. II. Preliminary results in the cognitively deteriorated. Journal of the American Geriatrics Society, 1986, Volume: 34, Issue:10 Topics: Activities of Daily Living; Aged; Aggression; Cognition Disorders; Confusion; Female; Haloperidol; H	1986
High-dose intravenous haloperidol in agitated cardiac patients. Journal of clinical psychopharmacology, 1986, Volume: 6, Issue:6 Topics: Coronary Disease; Dose-Response Relationship, Drug; Haloperidol; Humans; Infusions, Intravenous; Psy	1986
Benzodiazepines combined with neuroleptics for management of severe disruptive behavior. Psychosomatics, 1986, Volume: 27, Issue:1 Suppl Topics: Adolescent; Adult; Aged; Dangerous Behavior; Drug Therapy, Combination; Female; Haloperidol; Hospita	1986
Alternative approaches in the treatment of psychotic agitation. Psychosomatics, 1986, Volume: 27, Issue:1 Suppl Topics: Combined Modality Therapy; Haloperidol; Humans; Injections, Intramuscular; Lorazepam; Psychomotor Ag	1986
Neuroleptic malignant syndrome complicating closed head injury. Neurosurgery, 1986, Volume: 18, Issue:2 Topics: Adult; Brain Injuries; Bromocriptine; Haloperidol; Humans; Male; Neuroleptic Malignant Syndrome; Psy	1986
Agitation in closed head injury: haloperidol effects on rehabilitation outcome. Archives of physical medicine and rehabilitation, 1985, Volume: 66, Issue:1 Topics: Amnesia; Brain; Brain Injuries; Coma; Haloperidol; Humans; Prognosis; Psychomotor Agitation; Retrosp	1985
Suicide attempts associated with akathisia. The American journal of psychiatry, 1985, Volume: 142, Issue:4 Topics: Adult; Akathisia, Drug-Induced; Female; Fluphenazine; Haloperidol; Humans; Impulsive Behavior; Male;	1985
Emergency treatment of acute psychosis, agitation, and anxiety. Hospital & community psychiatry, 1985, Volume: 36, Issue:4 Topics: Anxiety Disorders; Diazepam; Droperidol; Emergencies; Haloperidol; Humans; Lorazepam; Panic; Propran	1985
Successful treatment of neuroleptic-induced akathisia with baclofen and clonazepam. A case report. European neurology, 1985, Volume: 24, Issue:4 Topics: Akathisia, Drug-Induced; Baclofen; Benzodiazepinones; Clonazepam; Haloperidol; Humans; Male; Middle	1985
Use of high-dose intravenous haloperidol in the treatment of agitated cardiac patients. Journal of clinical psychopharmacology, 1985, Volume: 5, Issue:6 Topics: Coronary Disease; Female; Haloperidol; Humans; Injections, Intravenous; Male; Middle Aged; Psychomot	1985

haloperidol and Psychomotor Agitation